

Publikationen aus der Klinik und Poliklinik  
für Psychiatrie und Psychotherapie 2025  
LMU München, Nussbaumstr. 7, 80336 München

Anzahl Publikationen: 349  
Summe IF: 2279.2

1. Addington J, Liu L, Braun A, Auther A, Calkins ME, Cornblatt BA, Corcoran CM, Fusar-Poli P, Kerr MJ, Mourgues-Codern CV, Nunez AR, Oliver D, Strauss GP, Walsh BC, Alameda LK, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Carrion RE, Chen EYH, Choi J, Coleman MJ, Conus P, Diaz-Caneja CM, Dwyer D, Ellman LM, Faghankhani M, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui C, Jacobs GR, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Marcy PJ, Mathalon DH, Mittal VA, Nordentoft M, Pearlson GD, Penzel N, Perez J, Perkins DO, Powers AR 3rd, Rogers J, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Thompson A, Thompson JL, Uptegrove R, Verma S, Wang J, Wastler HM, Wickham A, Rossum IW, Wolf DH, Bouix S, Pasternak O, Kahn RS, Bearden CE, Kane JM, McGorry PD, Buccilli K, Nelson B, Shenton ME, Woods SW; Accelerating Medicines Partnership® -Schizophrenia; Yung AR Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program. Schizophrenia (Heidelb). 2025 Apr 3;11(1):54. doi: 10.1038/s41537-025-00556-7. PMID: 40180953. IF 4.5
2. Addington J, Liu L, Chu M, Jungert K, Penzel N, Pasternak O, Farina E, Carrion RE, Corcoran CM, Mittal VA, Strauss GP, Yung AR, Alameda L, Arango C, Borders O, Bouix S, Breitborde NJK, Broome MR, Cadenhead KS, Castillo-Passi RI, Chen EYH, Choi J, Coleman MJ, Conus P, Diaz-Caneja CM, Ellman LM, Poli PF, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Kapur T, Kelly S, Kerr MJ, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Marcy PJ, Mathalon DH, Mourgues C, Nordentoft M, Nunez AR, Pearlson GD, Perez J, Perkins DO, Powers AR 3rd, Rogers J, Sabb FW, Schiffman J, Seitz-Holland J, Shah JL, Silverstein SM, Smesny S, Stone WS, Thompson JL, Uptegrove R, Verma S, Wang J, Wolf DH, Zhang T, Addamo L, Buccilli K, Dwyer D, Todd S, Cho YT, Fontenau C, Tamayo Z, Bearden CE, Kane JM, McGorry PD, Kahn RS, Shenton ME, Woods SW; Accelerating Medicines Partnership® Schizophrenia Nelson Barnaby; Calkins ME Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program. Schizophr Bull Open. 2025 Aug 25;6(1):sgaf012. doi: 10.1093/schizbullopen/sgaf012. eCollection 2025 Jan. PMID: 40861307. IF 2.4

3. **Addington J, Shalev A, Liu L, Jahraus C, Chu M, Farina E, Fusar Poli P, Marcy PJ, Nunez AR, Calkins ME, Alameda L, Arango C, Borders O, Bouix S, Breitborde NJK, Broome MR, Cadenhead KS, Carrion RE, Castillo-Passi RI, Chen EYH, Choi J, Coleman MJ, Conus P, Corcoran CM, Diaz-Caneja CM, Ellman LM, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Kapur T, Kelly S, Kerr MJ, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Mathalon DH, Mittal VA, Mourgues C, Nordentoft M, Pasternak O, Pearlson GD, Penzel N, Perez J, Perkins DO, Powers AR 3rd, Rogers J, Sabb FW, Schiffman J, Seitz-Holland J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Thompson JL, Upthegrove R, Verma S, Wang J, Wolf DH, Yung AR, Zhang T, Addamo L, Buccilli K, Todd S, Dwyer D, Bearden CE, Kane JM, McGorry PD, Kahn RS, Shenton ME, Woods SW; Accelerating Medicines Partnership® Schizophrenia Nelson Barnaby**  
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program.  
Schizophr Bull Open. 2025 Aug 25;6(1):sgaf013. doi:  
10.1093/schizbullopen/sgaf013. eCollection 2025 Jan. PMID: 40861306. IF 2.4
  
4. **Aksar A, Lutz J, Wagner E, Strube W, Luykx JJ, Hasan A**  
Vaccination and clozapine use: a systematic review and an analysis of the VAERS database.  
Eur Arch Psychiatry Clin Neurosci. 2025 Feb;275(1):141-162. doi:  
10.1007/s00406-023-01729-0. PMID: 38165458. IF 3.9
  
5. **Albantakis L, Weindel L, Brandi ML, Zillekens IC, Henco L, Thaler H, Schliephake L, Schilbach L**  
Alexithymic and autistic traits differentially predict personality disorder dimensions.  
Autism. 2025 Oct;29(10):2463-2476. doi: 10.1177/13623613251338650.  
PMID: 40452234. IF 5.7
  
6. **Alexopoulos P, Bountoulis C, Katirtzoglou E, Kosmidis MH, Siarkos K, Yannakoulia M, Dardiotis E, Skondra M, Hadjigeorgiou G, Perneczky R, Sakka P, Georgiou EZ, Charalampopoulou M, Felemegkas P, Leroi I, Batsidis A, Perna L, Politis A, Scarneas N, Economou P**  
The potential of depressive symptoms to identify cognitive impairment in ageing.  
Eur J Ageing. 2025 Feb 25;22(1):7. doi: 10.1007/s10433-025-00837-1.  
PMID: 40000465. IF 3.8
  
7. **Allott K, Yassin W, Alameda L, Billah T, Borders O, Buccilli K, Carrión RE, Castillo-Passi RI, Cho KIK, Chin K, Coleman MJ, Colton BL, Corral S, Dwyer D, Gundersen KB, Gur RC, Hoftman GD, Jacobs GR, Kelly S, Lewandowski KE, Marcy PJ, Matneja P, McLaughlin D, Nunez AR, Parsa S, Penzel N, Ray S, Reinen JM, Ruparel K, Sand MS, Santorelli G, Seitz-Holland J, Spark J, Tamayo Z, Thompson A, Tod S, Wannan CMJ, Wickham A, Wood SJ, Zoupou E, Addington J, Anticevic A, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Diaz-Caneja CM, Mathalon DH, Mittal VA, Nordentoft M, Pearlson GD, Perkins DO, Perez J, Powers AR 3rd, Rogers J, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Strauss GP, Thompson JL, Upthegrove R, Verma SK, Wang J, Wolf DH, Pasternak O, Bouix S, McGorry PD, Kane JM, Kahn RS, Bearden CE, Shenton ME, Woods SW, Nelson B; Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ); Stone WS**  
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia

Program: harmonization priorities and strategies in a diverse international sample. Schizophrenia (Heidelb). 2025 Mar 24;11(1):49. doi: 10.1038/s41537-025-00578-1. PMID: 40128256. IF 4.5

8. **Arribas M, Barnby JM, Patel R, McCutcheon RA, Kornblum D, Shetty H, Krakowski K, Stahl D, Koutsouleris N, McGuire P, Fusar-Poli P, Oliver D**  
Longitudinal evolution of the transdiagnostic prodrome to severe mental disorders: a dynamic temporal network analysis informed by natural language processing and electronic health records.  
Mol Psychiatry. 2025 Jul;30(7):2931-2942. doi: 10.1038/s41380-025-02896-3. PMID: 39843546. IF 10.4
9. **Aymerich C, Pedruzo B, Salazar de Pablo G, Labad J, McCutcheon R, Pillinger T, González-Torres MÁ, Sanchez-Gistau V, Oliver D, Alonso-Alconada D, Navalón P, Sugranyes G, Vieta E, Arango C, McGuire P, Fusar-Poli P, Catalan A**  
Do biological alterations precede the onset of psychosis? A systematic review and meta-analysis of immune, cardiometabolic, prolactin and HPA axis alterations in clinical high-risk for psychosis.  
Brain Behav Immun. 2025 Aug;128:219-233. doi: 10.1016/j.bbi.2025.04.009. PMID: 40204113. IF 7.5
10. **Backmund M, Zámbo GG, Schöfl S, Soyka M**  
Cannabis Use in Opioid Maintenance Therapy: Prevalence, Clinical Correlates and Reasons for Use.  
Brain Sci. 2025 Jun 29;15(7):699. doi: 10.3390/brainsci15070699. PMID: 40722291. IF 3.4
11. **Batra A, Jähne A, Rüther T**  
Tabakabhängigkeit (ICD-10 F17.2).  
In: Voderholzer U, Hohagen F (Hrsg)  
Therapie psychischer Erkrankungen. State of the Art 2026.  
Elsevier/Urban & Fischer, 2025, 21. Auflage, S. 92-108
12. **Bauer T, Brendel M, Zaganjori M, Bernhardt AM, Jäck A, Stöcklein S, Scheifele M, Levin J, van Eimeren T, Drzezga A, Sabri O, Barthel H, Perneczky R, Höglinger G, Franzmeier N, Gnörich J; German Imaging Initiative for Tauopathies (GII4T)**  
Pragmatic algorithm for visual assessment of 4-Repeat tauopathies in [<sup>18</sup>F]PI-2620 PET Scans.  
Neuroimage. 2025 Feb 1;306:121001. doi: 10.1016/j.neuroimage.2025.121001. PMID: 39798829. IF 5.3
13. **Bauman T, Kolar DR, Correll CU, Haas V, Voderholzer U**  
Impact of Antipsychotic Medications on Weight Gain and Eating Disorder-Related Psychopathology in Adult Inpatients with Anorexia Nervosa.  
Pharmacopsychiatry. 2025 Mar;58(2):80-87. doi: 10.1055/a-2436-9552. PMID: 39561817. IF 2.3
14. **Bauman T, Voderholzer U**  
[Pharmacotherapy of eating disorders-An update].  
Nervenarzt. 2025 May;96(3):230-237. doi: 10.1007/s00115-025-01804-y. PMID: 39976724. IF 1.1

15. **Baumeister H, Gellersen HM, Polk SE, Lattmann R, Wuestefeld A, Wisse LEM, Glenn T, Yakupov R, Stark M, Kleineidam L, Roeske S, Morgado BM, Esselmann H, Brosseon F, Ramirez A, Lüsebrink F, Synofzik M, Schott BH, Schmid MC, Hetzer S, Dechent P, Scheffler K, Ewers M, Hellmann-Regen J, Ersözlü E, Spruth E, Gemenetzi M, Fliessbach K, Bartels C, Rostamzadeh A, Glanz W, Incesoy EI, Janowitz D, Rauchmann BS, Kilimann I, Sodenkamp S, Coenjaerts M, Spottke A, Peters O, Priller J, Schneider A, Wiltfang J, Buerger K, Perneczky R, Teipel S, Laske C, Wagner M, Ziegler G, Jessen F, Düzel E, Berron D; DELCODE study group**  
Disease stage-specific atrophy markers in Alzheimer's disease.  
Alzheimers Dement. 2025 Jul;21(7):e70482. doi: 10.1002/alz.70482.  
PMID: 40691867. IF 12.8
16. **Bechdorf A, Correll CU, Hellenschmidt T, Holzner L, von Hardenberg L, Jäckel D, Kambeitz J, Koutsouleris N, Kusserow N, Leopold K, Meisenzahl E, Pfennig A, Reif A, Reininghaus U, Schellong M, Shmulovich O, Uhlhaas PJ, Domanska OM**  
[Integrated youth mental health services - Low-threshold, integrated programs for young people in mental health crises : International experiences and the current situation in Germany].  
Nervenarzt. 2025 Nov;96(6):557-563. doi: 10.1007/s00115-025-01895-7.  
PMID: 40905984. IF 1.1
17. **Becker-Sadzio J, Brendel B, Weller S, Bornheimer E, Mehlig U, Padberg F, Vogelmann U, Kammer T, Strube W, Martus P, Fallgatter AJ, Plewnia C**  
Effectiveness of rTMS compared to SSRI as early treatment of depression - study protocol of a randomized controlled trial (Early-TMS).  
Eur Arch Psychiatry Clin Neurosci. 2025 Sep;275(6):1839-1849. doi: 10.1007/s00406-025-01975-4. PMID: 39985658. IF 3.9
18. **Bellato A, Raduà J, Stocker A, Lockman MS, Lall A, Ravisankar V, Obiokafor S, Machell E, Haq S, Albiaa D, Cabras A, Leffa DT, Manuel C, Parlatini V, Riccioni A, Correll CU, Fusar-Poli P, Solmi M, Cortese S**  
Reporting and Representation of Race and Ethnicity in Clinical Trials of Pharmacotherapy for Mental Disorders: A Meta-Analysis.  
JAMA Psychiatry. 2025 Jul 1;82(7):663-670. doi: 10.1001/jamapsychiatry.2025.0666. PMID: 40332916. IF 18.0
19. **Bergmann H, Neumeier E, Kühnl R, Schneider F, Heinemann A, Hoch E**  
Drug-Related Deaths in Germany.  
Dtsch Arztebl Int. 2025 Jun 13;122(12):336-337. doi: 10.3238/arztebl.m2025.0027. PMID: 40637479. IF 8.7
20. **Bergmann H, Schneider F, Kuban MA, Schäffer D, Hoch E, Matos E, Neumeier E**  
Drug consumption rooms in Germany 2023.  
Suchttherapie 2025; 26(3): 124-132. IF 0.2
21. **Beutel A, Sanftenberg L, Friemel CM, Kosilek RP, Schauer M, Elbert T, Reips UD, Schubert T, Gehrke-Beck S, Schmidt K, Gensichen J; PICTURE study group**  
Patient perspectives on stress after ICU and a short primary care based psychological intervention - results from a qualitative sub-study of the PICTURE trial.  
BMC Prim Care. 2025 Jan 15;26(1):12. doi: 10.1186/s12875-024-02698-6. PMID: 39815198. IF 2.9

22. **Bienek O, Allott K, Antonucci L, Bertolino A, Bonivento C, Borgwardt S, Brambilla P, Chisholm K, Dannlowski U, Lichtenstein TK, Kambeitz J, Kambeitz-Illankovic L, Koutsouleris N, Lencer R, Griffiths SL, Maggioni E, Meisenzahl E, Pantelis C, Rosen M, Ruhrmann S, Salokangas RKR, Stainton A, Surmann M, Upthegrove R, Wenzel J, Wood SJ, Romer G, Müller JM; PRONIA Consortium**  
Neurocognitive dysfunction in adolescents with recent onset major depressive disorder: a cross-sectional comparative study.  
Eur Child Adolesc Psychiatry. 2025 Jun;34(6):1873-1882. doi: 10.1007/s00787-024-02599-0. PMID: 39503777. IF 4.4
23. **Bierlich AM, Bloch C, Spyra T, Lanz C, Falter-Wagner CM, Vogeley K**  
Corrigendum: An evaluation of the German version of the Sensory Perception Quotient from an expert by experience perspective.  
Front Psychol. 2025 Mar 25;16:1565601. doi: 10.3389/fpsyg.2025.1565601. eCollection 2025. PMID: 40207125. IF -
24. **Bierlich AM, Plank IS, Scheel NT, Keeser D, Falter-Wagner CM**  
Neural processing of social reciprocity in autism.  
Neuroimage Clin. 2025;46:103793. doi: 10.1016/j.nicl.2025.103793. PMID: 40315681. IF 4.2
25. **Bierlich AM, Scheel NT, Koehler JC, Bloch C, Plank IS, Falter-Wagner CM**  
Attenuated behavioral interpersonal synchrony in autistic adults is not explained by perception of timing.  
Sci Rep. 2025 Jun 20;15(1):20157. doi: 10.1038/s41598-025-05395-1. PMID: 40542016. IF 4.9
26. **Bitter I, Katona L, Falkai P, Czobor P**  
The importance of incorporation of real-world evidence into the guidelines on the pharmacological treatment of schizophrenia.  
Eur Arch Psychiatry Clin Neurosci. 2025 Aug;275(5):1521-1523. doi: 10.1007/s00406-024-01938-1. PMID: 39535551. IF 3.9
27. **Blackman G, Byrne R, Gill N, Fanshawe JB, Bell V, Watson C, Koutsouleris N, Fusar-Poli P, Pollak TA, McGuire P**  
How common is secondary psychosis? Estimates from a systematic review and meta-analysis.  
World Psychiatry. 2025 Feb;24(1):145-146. doi: 10.1002/wps.21292. PMID: 39810668. IF 79.5
28. **Blake KV, Hilbert K, Ipser JC, Han LKM, Bas-Hoogendam JM, Åhs F, Bauer J, Beesdo-Baum K, Björkstrand J, Blanco-Hinojo L, Böhnlein J, Bülow R, Cano M, Cardoner N, Caseras X, Dannlowski U, Fredrikson M, Goossens L, Grabe HJ, Grotegerd D, Hahn T, Hamm A, Heinig I, Herrmann MJ, Hofmann D, Jamalabadi H, Jansen A, Kindt M, Kircher T, Klahn AL, Koelkebeck K, Krug A, Leehr EJ, Lotze M, Margraf J, Muehlhan M, Nenadić I, Peñate W, Pittig A, Plag J, Pujol J, Richter J, Ridderbusch IC, Rivero F, Schäfer A, Schäfer J, Schienle A, Schrammen E, Schruers K, Seidl E, Stark RM, Straube B, Straube T, Ströhle A, Teutenberg L, Thomopoulos SI, Ventura-Bort C, Visser RM, Völzke H, Wabnegger A, Wendt J, Wittchen HU, Wittfeld K, Yang Y, Zilverstand A, Zwanzger P, Schmaal L, Aghajani M, Pine DS, Thompson PM, van der Wee NJA, Stein DJ, Lueken U, Groenewold NA**  
Brain Aging in Specific Phobia: An ENIGMA-Anxiety Mega-Analysis.  
medRxiv [Preprint]. 2025 Mar 20:2025.03.19.25323474. doi: 10.1101/2025.03.19.25323474 .PMID: 40166564. IF -

29. **Böge K, Jüttner J, Stratmann D, Leucht S, Moritz S, Schomerus G, Klingberg S, Hasan A, Lincoln T, Bajbouj M, Falkai P, Hahn E**  
[Changing Psychiatric Terms - Why Schizophrenia Needs to be Renamed in the 21st Century].  
Psychiatr Prax. 2025 Apr;52(3):125-128. doi: 10.1055/a-2517-2641.  
PMID: 40216388. IF 0.9
30. **Bommhardt T, Peschl J, Schultze-Lutter F, Koutsouleris N, Meisenzahl E, Köberlein-Neu J; CARE Study Group**  
Enhancing early detection and treatment of psychosis in Germany: a protocol for the health economic evaluation of an artificial intelligence-guided complex intervention.  
BMJ Open. 2025 Jun 18;15(6):e103151. doi: 10.1136/bmjopen-2025-103151.  
PMID: 40533222. IF 2.5
31. **Borchert T, Heinig I, Arolt V, Bartnick C, Dannlowski U, Deckert J, Domschke K, Fydrich T, Goerigk S, Hamm AO, Hollandt M, Hoyer J, Kircher T, Koelkebeck K, Lueken U, Margraf J, Neudeck P, Pauli P, Richter J, Rief W, Schneider S, Straube B, Ströhle A, Wittchen HU, Pittig A**  
Joy beyond fear: Positive emotions after exposure in patients with anxiety disorders and their link to threat expectancy and treatment outcome.  
Behav Res Ther. 2025 Dec;195:104880. doi: 10.1016/j.brat.2025.104880.  
PMID: 41086598. IF 4.3
32. **Boudriot E, Stephan M, Rabe F, Smigielski L, Schmitt A, Falkai P, Ziller MJ, Rossner MJ, Homan P, Papiol S, Raabe F**  
Genetic Analysis of Retinal Cell Types in Neuropsychiatric Disorders.  
JAMA Psychiatry. 2025 Mar 1;82(3):285-295. doi: 10.1001/jamapsychiatry.2024.4230. PMID: 39775833. IF 18.0
33. **Brandt L, Augustinavicius J, Fusar-Poli P, Hasan A, Patel VH, Simon J, Luykx JJ**  
Climate change and mental health: announcing a new Lancet Psychiatry Commission.  
Lancet Psychiatry. 2025 Nov;12(11):811-813.  
doi: 10.1016/S2215-0366(25)00274-3. PMID: 40945519. IF 21.1
34. **Brunnauer A, Graw M, Laux G (Hrsg)**  
Fahreignung bei psychischen Erkrankungen.  
MWV Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2025,  
2. Auflage
35. **Brunnauer A, Laux G**  
Affektive Störungen.  
In: Brunnauer A, Graw M, Laux G (Hrsg)  
Fahreignung bei psychischen Erkrankungen.  
MWV Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2025,  
2. Auflage S. 101-109.
36. **Brunnauer A, Strohbeck-Kühner P**  
Anforderungen an die Leistungsfähigkeit.  
In: Brunnauer A, Graw M, Laux G (Hrsg)  
Fahreignung bei psychischen Erkrankungen.  
MWV Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2025,  
2. Auflage S. 46-54.

37. **Brunoni AR, Padberg F**  
Spaced Transcranial Direct Current Stimulation for Depression: The Road Less Traveled.  
Am J Psychiatry. 2025 Mar 1;182(3):231-233. doi: 10.1176/appi.ajp.20241088. PMID: 40022529. IF 15.9
38. **Burkhardt G, Blackwell SE, Chen M, Feldmann L, Björklund J, Dechantsreiter E, Bulubas L, Goerigk S, Keeser D, Falkai P, Greimel E, Bechmann P, Schulte-Körne G, Hasan A, Strube W, Padberg F**  
Intermittent theta burst stimulation in adolescents and young adults with depressive disorders: protocol of a randomized, sham-controlled study with a sequential Bayesian design for adaptive trials.  
Eur Arch Psychiatry Clin Neurosci. 2025 Sep;275(6):1827-1838. doi: 10.1007/s00406-024-01926-5. PMID: 39387918. IF 3.9
39. **Campanella S, Arikan MK, Ilhan R, Sanader Vukadinovic B, Pogarell O**  
New Insights in the Treatment of Substance Use Disorders Thanks to Electrophysiological Tools.  
Clin EEG Neurosci. 2025 Nov;56(6):518-526. doi: 10.1177/15500594251324506. PMID: 40012240. IF 2.1
40. **Catalán A, Aymerich C, Rodríguez-Sánchez JM, Pedruzo B, Salazar de Pablo G, Gil P, Aguayo F, Acasuso G, Collado-Pérez A, Goena J, Ibarretxe O, Zorrilla I, González-Pinto A, Erkoreka L, Alonso-Alconada D, Fusar-Poli P, González-Torres MA**  
Peripheral inflammation and neurocognitive functioning in early psychosis: Specific associations of TNF- $\alpha$  and IL-6 with social cognition.  
Eur Psychiatry. 2025 Jul 10;68(1):e95. doi: 10.1192/j.eurpsy.2025.10063. PMID: 40637145. IF 7.9
41. **Catalan A, Salazar de Pablo G, Aymerich C, Guinart D, Goena J, Madaria L, Pacho M, Alameda L, Garrido-Torres N, Pedruzo B, Rubio JM, Gonzalez-Torres MA, Fusar-Poli P, Correll CU**  
"Short" Versus "Long" Duration of Untreated Psychosis in People with First-Episode Psychosis: A Systematic Review and Meta-Analysis of Baseline Status and Follow-Up Outcomes.  
Schizophr Bull. 2025 Sep 8;51(5):1206-1230. doi: 10.1093/schbul/sbae201. PMID: 39580760. IF 5.7
42. **Chang KY, Tik M, Mizutani-Tiebel Y, Taylor P, van Hattem T, Falkai P, Padberg F, Bulubas L, Keeser D**  
Dose-Dependent Target Engagement of a Clinical Intermittent Theta Burst Stimulation Protocol: An Interleaved Transcranial Magnetic Stimulation-Functional Magnetic Resonance Imaging Study in Healthy People.  
Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Aug;10(8):804-813. doi: 10.1016/j.bpsc.2024.08.009. PMID: 39182723. IF 4.9
43. **Chang MH, Waldeck JB, Stephan M, Kannaiyan N, de Almeida V, Boudriot E, Karali T, Röhl L, Fischer L, Demetriou D, Gabellini N, Galinski S, Schmitt A, Papiol S, Keeser D, Falkai P, Rossner MJ, Raabe FJ**  
iPSC-modelling reveals genetic associations and morphological alterations of oligodendrocytes in schizophrenia.  
Transl Psychiatry. 2025 Aug 16;15(1):287. doi: 10.1038/s41398-025-03509-x. PMID: 40819083. IF 7.5

44. **Cheng Y, He Y, Gopinath K, Billot B, Iglesias JE, Wu CY, Dodge H, Wills AM, Carlyle B, Kivisäkk P, Hyman BT, Arnold SE, Das S; Alzheimer's Disease Neuroimaging Initiative and for the European Prevention of Alzheimer's Disease (EPAD) Consortium**  
Brain MRI signatures across sex and CSF Alzheimer's disease biomarkers.  
Brain Commun. 2025 May 30;7(3):fcf210. doi: 10.1093/braincomms/fcaf210.  
eCollection 2025. PMID: 40503330. IF 4.5
45. **Cho H, Kim S, Son Y, Jang W, Kim HJ, Lee H, Lee S, Oh J, Kang J, Tsai AC, Shinn AK, Fond G, Boyer L, Solmi M, Woo S, Yon DK, Fusar-Poli P**  
Method-specific suicide mortality rates among older adults in 47 countries and territories, 1996-2021, with projections to 2050: a global time series and modelling study.  
Lancet Healthy Longev. 2025 Jul;6(7):100719. doi: 10.1016/j.lanhl.2025.100719.  
PMID: 40659027. IF 20.5
46. **Chodkiewicz J, Joanna M, Monika T, Michał Seweryn K, Möller-Leimkühler AM**  
The Gender-Sensitive Depression Screening GSDS-26 - Polish adaptation and validation of the tool and links to gender stereotypes.  
Psychiatr Pol. 2025 Feb 28;59(1):139-152. doi: 10.12740/PP/  
PMID: 38896459. IF 1.5
47. **Colbert SMC, Monson ET, Andreassen OA, Ayinde OO, Barr PB, Bejan CA, Ceja Z, Coon H, DiBlasi E, Edenberg HJ, Gelernter J, Hatoum A, Izotova A, Johnson EC, Kaufman EA, Kranzler HR, Koromina M, Lehto K, Myung W, Nurnberger JI Jr, Serretti A, Smoller JW, Stein MB, Zai CC, Erlangsen A, Gaine M, Martorell L, Sud R, Toma C, Bigdeli TB, Kimbrel NA, Ruderfer D, Docherty AR, Mann JJ, Mullins N; Psychiatric Genomics Consortium Suicide Working Group**  
Defining suicidality phenotypes for genetic studies: perspectives of the Psychiatric Genomics Consortium Suicide Working Group.  
Mol Psychiatry. 2025 Dec;30(12):6144-6154. doi: 10.1038/s41380-025-03271-y.  
PMID: 40999039. IF 10.4
48. **Correll CU, Cortese S, Solmi M, Boldrini T, Demyttenaere K, Domschke K, Fusar-Poli P, Gorwood P, Harvey PD, Keefe RSE, Knaevelsrud C, Kotov R, Nohr L, Rhee TG, Roe D, Rose M, Schneider LS, Slade M, Stein DJ, Sunkel C, McIntyre RS**  
Beyond symptom improvement: transdiagnostic and disorder-specific ways to assess functional and quality of life outcomes across mental disorders in adults.  
World Psychiatry. 2025 Oct;24(3):296-318. doi: 10.1002/wps.21338.  
PMID: 40948079. IF 79.5
49. **Cortese S, Bellato A, Gabellone A, Marzulli L, Matera E, Parlatini V, Petruzzelli MG, Persico AM, Delorme R, Fusar-Poli P, Gosling CJ, Solmi M, Margari L**  
Latest clinical frontiers related to autism diagnostic strategies.  
Cell Rep Med. 2025 Feb 18;6(2):101916. doi: 10.1016/j.xcrm.2024.101916.  
PMID: 39879991. IF 14.0

50. **Cruchaga C, Timsina J, Jiang C, McCartney D, Tao F, Dalmasso MC, Najar J, Anastasi F, Ohlei O, Puerta R, Bradley J, Western D, Ali M, Wang C, Yang C, Wu Y, Liu M, Budde J, Williams J, Mahoney R, Castillo A, Hohman T, Dumitrescu L, Wang TC, Tesi N, Kern S, Waern M, Skoog I, van Harten A, van der Flier W, Sánchez-Juan P, Rodriguez-Rodriguez E, Kleineidam L, Peters O, Schneider A, Küçükali F, Bellenguez C, Grenier-Boley B, Heikkinen S, de Rojas I, Rujescu D, Scherbaum N, Hausner L, Duzel E, Grimmer T, Wiltfang J, Vandenberghe R, Engelborghs S, Heilmann-Heimbach S, Schmid M, Teges T, Scarmeas N, Dols-Icardo O, Moreno F, Pérez-Tur J, Bullido MJ, Sanchez-Valle R, Álvarez V, Garcia-Gonzalez P, Mir P, Real L, Piñol-Ripoll G, García-Alberca JM, Seelaar H, Ramakers I, Papma J, Hulsman M, Laske C, Teipel S, Priller J, Perneczky R, Buerger K, Nöthen M, Lewczuk P, Kornhuber J, Maier W, Hampel H, Giegling I, Goldhardt O, Diehl-Schmid J, Andrade V, Heneka M, Froelich L, Vogelgsang J, Graff C, Thonberg H, Ullgren A, Papenberg G, Boland A, Deleuze JF, Wagner M, Jessen F, Holstege H, van Duijn C, Lebouvier T, Hanon O, Leinonen V, Soininen H, Herukka SK, Giedraitis V, Löwenmark M, Kilander L,...See abstract for full author list →**  
 GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy.  
 Res Sq [Preprint]. 2025 May 21;rs.3.rs-6597595. doi: 10.21203/rs.3.rs-6597595/v1.PMID: 40470240
51. **Csollarova K, Koletzko L, Le Thi TG, Wratil PR, Zhelyazkova A, Breiteneicher S, Stern M, Lupoli G, Schwerdt T, Choukér A, Hornung V, Keppler OT, Adorjan K, Török HP, Koletzko S; Members of RisCoin Study Group**  
 Factors Associated with Impaired Humoral Immune Response to mRNA Vaccines in Patients with Inflammatory Bowel Disease: A Matched-Cohort Analysis from the RisCoin Study.  
 Vaccines (Basel). 2025 Jun 23;13(7):673. doi: 10.3390/vaccines13070673. PMID: 40733650. IF 3.5
52. **Cuesta MJ, Sánchez-Torres AM, Moreno-Izco L, García de Jalón E, Gil-Berrozpe GJ, Peralta V; SEGPEPs Group**  
 Long-term trajectories of clinical staging in first-episode psychosis and their associated cognitive outcome: A 21-year follow-up study.  
 Span J Psychiatry Ment Health. 2025 Apr-Jun;18(2):116-124. doi: 10.1016/j.sjpmh.2024.02.001. PMID: 38423184. IF 2.6
53. **Damiani S, D'Imperio A, Radua J, Fortea L, Calò M, Crippa A, Esposito CM, Lumer ELL, Patron S, Peviani A, Piccolo A, Provenzani U, Santilli F, Spallarossa C, Fusar-Poli L, Papanastasiou E, Cella M, Patel R, Galderisi S, Leucht S, Stahl D, Fusar-Poli P**  
 A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics.  
 Psychiatry Res. 2025 May;347:116406. doi: 10.1016/j.psychres.2025.116406. PMID: 40015036. IF 5.1
54. **da Silva PHR, Vanderhasselt MA, Pilloni G, Charvet L, Padberg F, Bikson M, Brunoni AR, Razza LB**  
 Challenges and future directions of Transcranial Direct Current Stimulation for Depression: insights from a systematic review and meta-analysis.  
 Braz J Psychiatry. 2025; 47:e20243989. doi: 10.47626/1516-4446-2024-3989. PMID: 40089991. IF 2.9

55. **Datta N, Matheson B, Plessow F, Citron K, Le Grange D, Schlegl S, Lock J**  
The Impact of Family-Based Treatment for Adolescent Anorexia Nervosa on Compulsive Exercise Attitudes and Behaviors.  
Int J Eat Disord. 2025 Feb;58(2):446-451. doi: 10.1002/eat.24334.  
PMID: 39579160. IF 4.7
  
56. **de Bruin H, Groot C, Barthel H, Bischof GN, Blazhenets G, Boellaard R, Boon BDC, Brendel M, Cash DM, Coath W, Day GS, Dickerson BC, Doering E, Drzezga A, van Dyck CH, van Eimeren T, van der Flier WM, Fredericks CA, Fryer TD, van de Giessen E, Gordon BA, Graff-Radford J, Grinberg LT, Hansson O, Hobbs DA, Hoenig MC, Höglinger G, Irwin DJ, Jones PS, Josephs KA, Katsumi Y, La Joie R, Lee EB, Levin J, Malpetti M, McGinnis SM, Mecca AP, Mohanty R, Nasrallah IM, O'Brien JT, O'Dell RS, Palleis C, Perneczky R, Phillips JS, Putcha D, Rabinovici GD, Rahmouni N, Rosa-Neto P, Rowe JB, Rullmann M, Sabri O, Saur D, Schildan A, Schott JM, Schroeter ML, Seeley WW, Servaes S, Sintini I, Smith R, Spina S, Stevenson J, Stomrud E, Strandberg O, Therriault J, Tideman P, Touroutoglou A, Trainer AE, Visser D, Wekselman F, Weston PSJ, Whitwell JL, Wolk DA, Yong K, Pijnenburg YAL, Franzmeier N, Ossenkoppele R**  
Connectivity as a universal predictor of tau progression in atypical Alzheimer's disease.  
Brain. 2025 Nov 4;148(11):3893-3912. doi: 10.1093/brain/awaf279.  
PMID: 40810361. IF 12.6
  
57. **De Matos EG, Buhler A, Thrul J, Hoch E**  
Is school-based cannabis prevention effective, and when? A review of reviews.  
Suchttherapie 2025; 26(2): 69-76. IF 0.2
  
58. **Dieffenbacher AL, Meule A, Voderholzer U**  
Purging frequency and number of purging methods as indicators of severity in bulimia nervosa: Interactive effects with binge eating episodes.  
Eur Eat Disord Rev. 2025 Mar;33(2):343-359. doi: 10.1002/erv.3147.  
PMID: 39460725. IF 3.2
  
59. **Diehm ML, Kunz JI, Goerigk S, Wolf J, Lange J, Jobst A, Padberg F, Reinhard MA**  
Reciprocal Dynamics of Therapeutic Alliance and Depressive Symptoms in Inpatient Cognitive Behavioural Analysis System of Psychotherapy: The Role of Attachment Insecurity.  
Clin Psychol Psychother. 2025 Nov-Dec;32(6):e70200. doi: 10.1002/cpp.70200.  
PMID: 41355729. IF 2.9
  
60. **Diemer JE, Sich M, Lange B, Müller M, Koller M, Schäfer P, Meixner G, Brunnauer A, Zwanzger P**  
Automated interaction may reduce emotional reactivity in VR: a randomized study with healthy participants.  
Front Virtual Real 2025; 6: 1536968. IF 3.9
  
61. **Dinges M, Möller-Leimkühler AM (Hg).**  
Gewalterfahrungen von Jungen und Männern und die Folgen für ihre Gesundheit.  
Psychosozial Verlag 2025.

62. **Dudeck L, Nussbaumer M, Nickl-Jockschat T, Guest PC, Dobrowolny H, Meyer-Lotz G, Zhao Z, Jacobs R, Schiltz K, Fernandes BS, Steiner J**  
Differences in Blood Leukocyte Subpopulations in Schizophrenia: A Systematic Review and Meta-Analysis.  
JAMA Psychiatry. 2025 May 1;82(5):492-504. doi: 10.1001/jamapsychiatry.2024.4941. PMID: 40042836. IF 18.0
63. **Ebert C, Vogel M, Gensichen J, Reif H, Gröger L, Junker L, Ehring T, Hasan A, Leucht S, Lochbühler K; POKAL-Group**  
Evaluation of a transdiagnostic mental health intervention in German primary care: study protocol for a parallel-group, two-arm, cluster randomised controlled pilot study.  
Pilot Feasibility Stud. 2025 Jan 31;11(1):13. doi: 10.1186/s40814-025-01597-6. PMID: 39891264. IF 2.1
64. **Eckardt F, Mittas R, Horlava N, Schiefelbein J, Asani B, Michalakakis S, Gerhardt M, Priglinger C, Keeser D, Koutsouleris N, Priglinger S, Theis F, Peng T, Schworm B**  
Deep Learning-Based Retinal Layer Segmentation in Optical Coherence Tomography Scans of Patients with Inherited Retinal Diseases.  
Klin Monbl Augenheilkd. 2025 Sep;242(9):903-911. doi: 10.1055/a-2227-3742. PMID: 38086412. IF 1.1
65. **Eder J, Glocker C, Barton B, Sarisik E, Popovic D, Lämmermann J, Knaf A, Beqiri-Zagler A, Engl K, Rihs L, Pfeiffer L, Schmitt A, Falkai P, Simon MS, Musil R**  
Who is at risk for weight gain after weight-gain associated treatment with antipsychotics, antidepressants, and mood stabilizers: A machine learning approach.  
Acta Psychiatr Scand. 2025 Mar;151(3):231-244. doi: 10.1111/acps.13684. PMID: 38561235. IF 4.7
66. **Ehler J, Klawitter F, von Möllendorff F, Zacharias M, Fischer DC, Danckert L, Bajorat R, Hackenberg J, Bertsche A, Loebermann M, Geerdes-Fenge H, Fleischmann R, Klinkmann G, Schramm P, Schober S, Petzold A, Perneczky R, Saller T**  
No substantial neurocognitive impact of COVID-19 across ages and disease severity: a multicenter biomarker study of SARS-CoV-2 positive and negative adult and pediatric patients with acute respiratory tract infections.  
Infection. 2025 Apr;53(2):593-605. doi: 10.1007/s15010-024-02406-7. PMID: 39352661. IF 3.9
67. **Endres D, Baldermann JC, Schiele MA, Jelinek L, Domschke K, Voderholzer U**  
[Update on obsessive-compulsive and related disorders].  
Nervenarzt. 2025 Jul;96(4):403-415. doi: 10.1007/s00115-025-01845-3. PMID: 40576724. IF 1.1
68. **Endres D, Baldermann JC, Schiele MA, Jelinek L, Domschke K, Voderholzer U**  
[Update on obsessive-compulsive and related disorders].  
Psychotherapie 2025; 70(6): 416-428. IF 0.8
69. **Endres D, Schiele MA, von Zedtwitz K, Dressle RJ, Maier A, Hohagen F, Baldermann JC, Coenen VA, Jelinek L, Domschke K, Voderholzer U**  
Obsessive-compulsive disorder - A state-of-the-art review.  
Neurosci Biobehav Rev. 2025 Oct;177:106320. doi: 10.1016/j.neubiorev.2025.106320. PMID: 40850533. IF 8.5

70. **Engchuan W, Shanta O, Kumar K, MacDonald JR, Thiruvahindrapuram B, Hamdan O, Klein M, Maihofer A, Guevara J, Hong O, Huguet G, Sacks M, Ahangari M, Feitosa RMMW, Han K, Mendes M, Zhou X, Bautista NX, Pellecchia G, Wang Z, Merico D, Yuen RKC, Trost B, S nderby I, Adams MJ, Adolfsson R, Agartz I, Aiello AE, Alda M, Allardyce J, Amstadter AB, Andlauer TFM, Andreassen OA, Artigas MS, Austin SB, Ayub M, Baker DG, Bass N, Baune BT, Bayas M, Berger K, Biernacka JM, Bigdeli T, Bisson JI, Blackwood D, Boks M, Braff D, Bramon E, Breen G, Brueckl T, Bryant RA, Bulik CM, Buxbaum J, Cairns MJ, Caldas-de-Almeida JM, Campbell M, Champion D, Carr VJ, Castelao E, Chaumette B, Cichon S, Cohen D, Corvin A, Craddock N, Crosbie J, Czamara D, Dannlowski U, Degenhardt F, Delahanty DL, Dempfle A, Desachy G, Di Florio A, Dickerson FB, Djurovic S, Domschke K, Douglas L, Drange OK, Duncan LE, Edenberg HJ, Esko T, Faraone S, Feeny NC, Forstner AJ, Franke B, Frye M, Fu DJ, Fullerton JM, Gareeva A, Garvert L, Gatt JM, Gejman P, Geschwind DH, Giegling I, Glatt SJ, Glessner J, Goes FS, Gordon-Smith K, Grabe H, Green MJ, Green MF, Greenwood T, Grigoriu-Serbanescu M, Gur RE, Gur RC, Guzman-Parra J, Haavik J, Hahn ...See abstract for full author list →**  
Psychiatric disorders converge on common pathways but diverge in cellular context, spatial distribution, and directionality of genetic effects.  
medRxiv [Preprint]. 2025 Jul 16:2025.07.11.25331381.  
doi: 10.1101/2025.07.11.25331381. PMID: 40791676
71. **Engel RR**  
Erfassung von Antworttendenzen in multidimensionalen  
Pers nlichkeitsfrageb gen.  
In: R. Dohrenbusch (Hrsg.), Psychologische Begutachtung. Rechtliche Grundlagen  
- Leitlinien - Empfehlungen. Springer Berlin Heidelberg, 2025, S. 839-849.
72. **Engel RR**  
Regelbasierte Profilinterpretationen f r multidimensionale klinische  
Pers nlichkeitsst rungen.  
In: R. Dohrenbusch (Hrsg.), Psychologische Begutachtung. Rechtliche Grundlagen  
- Leitlinien – Empfehlungen. Springer Berlin Heidelberg, 2025, S. 491-497.
73. **Engels D, Flierl-Hecht A, Shalaginova G, Rek S, Keeser D, Reinhard MA, Padberg F, K mpfel T, Gerdes LA**  
Multiple sclerosis twin study reveals distinct genetic, disease-specific, and  
psychometric impact on coping with critical life events.  
J Neurol Sci. 2025 Feb 15;469:123381. doi: 10.1016/j.jns.2024.123381.  
PMID: 39798189. IF 3.1
74. **Erdekian A, Glock M, Huetter S, Rueb M, Riedinger D, Stoffers-Winterling J, Lindner S, Baum F, H lzel LP, T scher O, Lieb K, Adorjan K, Wiegand HF**  
[Utilization of mental health services in Germany during the first year  
of the COVID-19 pandemic-Systematic review and meta-analysis].  
Nervenarzt. 2025 May;96(3):257-265. doi: 10.1007/s00115-025-01812-y.  
PMID: 40053131. IF 1.1
75. **Falarowski C, Pieper E, Rabenstein A, Mallock-Ohnesorg N, Burgmann N, Franzen K, Gertzen M, Koller G, Nowak D, Rahofer A, Rieder B, de Oliveira Pinto Kise GR, Schulz T, Strohmeyer E, Laux P, Luch A, R ther T**  
Disposable e-cigarettes and their nicotine delivery, usage pattern, and  
subjective effects in occasionally smoking adults.  
Sci Rep. 2025 May 9;15(1):16270. doi: 10.1038/s41598-025-97491-5.  
PMID: 40346191. IF 4.9

76. **Falkai P**  
[German Brain Council - Promoting brain health, treating brain diseases].  
Fortschr Neurol Psychiatr. 2025 Dec;93(12):509. doi: 10.1055/a-2724-0041.  
PMID: 41330406. IF 0.5
77. **Falkai P**  
[Talks and Challenges of University Psychiatry and Psychotherapy in Germany].  
Fortschr Neurol Psychiatr 2025; 93:1-2. IF 0.5
78. **Falkai P**  
Psychische Erkrankungen frühzeitig erkennen.  
MMW Fortschr Med. 2025 Apr;167(7):5. doi: 10.1007/s15006-025-4669-1.  
PMID: 40237980. IF -
79. **Falkai P, Wagner E, John M, Yakimov V, Galderisi S, Bitter I, Dom G, Schmitt A, Gaebel W, Carpiello B, Hasan A**  
Developing the EPA guidance of pharmacological treatment of schizophrenia - results of a Delphi process.  
Eur Psychiatry. 2025 Jan 30;68(1):e26. doi: 10.1192/j.eurpsy.2024.1794.  
PMID: 39882596. IF 7.9
80. **Fazio L, Stolfa G, Passiatore R, Tavella A, Blasi G, Buciuman MO, Goldman AL, Haas SS, Kambeitz-Illankovic L, Koutsouleris N, Nicoli M, Popolizio T, Rampino A, Ruef A, Sambataro F, Selvaggi P, Ulrich W, Weinberger DR; Apulian Network on Risk for Psychosis, PRONIA Consortium; Bertolino A, Antonucci LA, Pergola G**  
Altered Brain-Behavior Association During Resting State is a Potential Psychosis Risk Marker.  
Adv Sci (Weinh). 2025 Jul;12(26):e2405700. doi: 10.1002/advs.202405700.  
PMID: 40176373. IF 14.1
81. **Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I, Hansen WP, Lin X, Prates-Baldez D, Salanti G, Keefe RSE, Engel RR, Leucht S**  
Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-Analysis.  
JAMA Psychiatry. 2025 Jan 1;82(1):47-56. doi: 10.1001/jamapsychiatry.2024.2890.  
PMID: 39412783. IF 18.0
82. **Feingold D, Tzur Bitan D, Ferri M, Hoch E**  
Predictors of effective therapy among individuals with Cannabis Use Disorder: a review of the literature.  
Eur Arch Psychiatry Clin Neurosci. 2025 Mar;275(2):341-353. doi: 10.1007/s00406-024-01781-4. PMID: 38493284. IF 3.9
83. **Fernando P, Strauss J, Wagner E, Löhrs L, Campana M, Falkai P, Hasan A, Papazova I**  
Early Treatment-Resistance in First Episode Psychosis.  
Pharmacopsychiatry. 2025 Mar;58(2):63-70. doi: 10.1055/a-2421-2411.  
PMID: 39547704. IF 2.3
84. **Ford E, Stone J, Oliver D, Fell B, Roque G, Robertson S, Fusar-Poli P, Greenwood K**  
Local adaptation and validation of a transdiagnostic risk calculator for first episode psychosis using mental health patient records.  
Front Psychiatry. 2025 Jul 22;16:1584719. doi: 10.3389/fpsy.2025.1584719.  
eCollection 2025. PMID: 40766924. IF 3.8

85. **Fountoulakis KN, Karakatsoulis G, Abraham S, Adorjan K, Ahmed HU, Alarcón RD, Arai K, Auwal SS, Berk M, Levaj S, Bobes J, Bobes-Bascaran T, Bourgin-Duchesnay J, Bredicean CA, Bukelskis L, Burkadze A, Abud IIC, Castilla-Puentes R, Cetkovich M, Colon-Rivera H, Corral R, Cortez-Vergara C, Crepin P, De Berardis D, Delgado SZ, De Lucena D, De Sousa A, Stefano RD, Dodd S, Elek LP, Elissa A, Erdelyi-Hamza B, Erzin G, Etchevers MJ, Falkai P, Farcas A, Fedotov I, Filatova V, Fountoulakis NK, Frankova I, Franza F, Frias P, Galako T, Garay CJ, Garcia-Álvarez L, García-Portilla MP, Gonda X, Gondek TM, González DM, Gould H, Grandinetti P, Grau A, Groudeva V, Hagin M, Harada T, Hasan TM, Razali S, Hilbig J, Hossain S, Iakimova R, Ibrahim M, Iftene F, Ignatenko Y, Irrarrazaval M, Ismail Z, Ismayilova J, Jakobs A, Jakovljević M, Jakšić N, Javed A, Kafali HY, Karia S, Kazakova O, Khalifa D, Khaustova O, Koh S, Kopishinskaia S, Kosenko K, Vadon NB, Lalljee A, Liewig J, Majid A, Malashonkova E, Malik K, Malik NI, Mammadzada G, Mandalia B, Marazziti D, Marčinko D, Martinez S, Matiekus E, Mejia G, Memon RS, Martínez XEM, Mickevičiūtė D, Milev R, Mohammed M, Molina-López A, Morozov P, Muhammad NS...**  
**See abstract for full author list →**  
Treatment and long-term outcome of mental disorders: The grim picture from a quasi-epidemiological investigation in 54,826 subjects from 40 countries. *Psychiatry Res.* 2025 Jun;348:116459. doi: 10.1016/j.psychres.2025.116459. PMID: 40179636. IF 5.1
86. **Fox NC, Belder C, Ballard C, Kales HC, Mummery C, Caramelli P, Ciccarelli O, Frederiksen KS, Gomez-Isla T, Ismail Z, Paquet C, Petersen RC, Perneczky R, Robinson L, Sayin O, Frisoni GB**  
Treatment for Alzheimer's disease. *Lancet.* 2025 Sep 27;406(10510):1408-1423. doi: 10.1016/S0140-6736(25)01329-7. PMID: 40997839. IF 109.0
87. **Fusar-Poli P, Estradé A, Mathi K, Mabilia C, Yanayirah N, Floris V, Figazzolo E, Esposito CM, Mancini M, Rosfort R, Catalan A, Baldwin H, Patel R, Stanghellini G, Ratcliffe M, Maj M**  
The lived experience of postpartum depression and psychosis in women: a bottom-up review co-written by experts by experience and academics. *World Psychiatry.* 2025 Feb;24(1):32-45. doi: 10.1002/wps.21264. PMID: 39810658. IF 79.5
88. **Gensichen J, Schmidt KFR, Sanftenberg L, Kosilek RP, Friemel CM, Beutel A, Dohmann J, Heintze C, Prescott HC, Reips UD, Schauer M, Lindemann D, Brettschneider C, Dreischulte T, Zwißler B, Elbert T; PICTURE study group**  
Effects of a general practitioner-led brief narrative exposure intervention on symptoms of post-traumatic stress disorder after intensive care (PICTURE): multicentre, observer blind, randomised controlled trial. *BMJ.* 2025 May 7;389:e082092. doi: 10.1136/bmj-2024-082092. PMID: 40335079. IF 55.1
89. **Gerbig P, Reinhard MA, Ababu H, Rek S, Amann BL, Adorjan K, Abera M, Padberg F, Jobst A**  
Are loneliness and social network size mediators between childhood adversity and depressive symptoms? A cross-sectional replication study in Ethiopia. *BMJ Open.* 2025 Aug 16;15(8):e088098. doi: 10.1136/bmjopen-2024-088098. PMID: 40819874. IF 2.5

90. **Gernert CC, Falter-Wagner CM, Noreika V, Jachs B, Jassim N, Gibbs K, Streicher J, Betts H, Bekinschtein TA**  
Correction: Stress in autism (STREAM): A study protocol on the role of circadian activity, sleep quality and sensory reactivity.  
PLoS One. 2025 Aug 5;20(8):e0329798. doi: 10.1371/journal.pone.0329798.  
eCollection 2025. PMID: 40763110. IF -
91. **Gifford G, Avila A, Kempton MJ, Fusar-Poli P, McCutcheon RA, Coutts F, Tognin S, Valmaggia L, de Haan L, van der Gaag M, Nelson B, Pantelis C, Riecher-Rössler A, Bressan R, Barrantes-Vidal N, Krebs MO, Glenthøj B, Ruhrmann S, Sachs G, Rutten BPF, van Os J, Eu-Gei High Risk Study, McGuire P**  
Do Cognitive Subtypes Exist in People at Clinical High Risk for Psychosis? Results From the EU-GEI Study.  
Schizophr Bull. 2025 Jul 7;51(4):1019-1029. doi: 10.1093/schbul/sbae133.  
PMID: 39052918. IF 5.7
92. **Gilsbach S, Leuchtenberger J, Herpertz-Dahlmann B, Voderholzer U, Konrad K, von Polier G, Seitz J, Fichter M**  
The roles of impulsivity, comorbid ADHD, and borderline personality disorder in patients with bulimia nervosa.  
Eat Weight Disord. 2025 Jan 18;30(1):7. doi: 10.1007/s40519-025-01713-8.  
PMID: 39825963. IF 3.5
93. **Glaus J, Karow A, Lambert M, Sowada P, Bröckel-Bundt K, Berndt C, Sauer C, Juckel G, Fallgatter AJ, Bechdolf A, Reif A, Matura S, Kittel-Schneider S, Stamm T, Kircher T, Falkenberg I, Jansen A, Correll CU, Fusar-Poli P, Bauer M, Pfennig A, Rohenkohl AC**  
Quality of life in persons at risk for bipolar disorder: a two year prospective-longitudinal observational cohort study (BipoLife).  
Int J Bipolar Disord. 2025 Feb 18;13(1):7. doi: 10.1186/s40345-025-00373-y.  
PMID: 39964389. IF 4.5
94. **Gosling CJ, Boisseleau L, Solmi M, Sandbank M, Jurek L, Nourredine M, Porcu G, Murgia E, Radua J, Fusar-Poli P, Kovarski K, Caparos S, Cartigny A, Cortese S, Delorme R**  
Complementary, alternative and integrative medicine for autism: an umbrella review and online platform.  
Nat Hum Behav. 2025 Dec;9(12):2610-2619. doi: 10.1038/s41562-025-02256-9.  
PMID: 40877399. IF 17.5
95. **Gosling CJ, Cortese S, Solmi M, Haza B, Vieta E, Delorme R, Fusar-Poli P, Radua J**  
metaConvert: an automatic suite for estimation of 11 different effect size measures and flexible conversion across them.  
Res Synth Methods. 2025 May;16(3):575-586. doi: 10.1017/rsm.2025.11.PMID: 41626934. IF 8.0
96. **Gosling CJ, Garcia-Argibay M, De Prisco M, Arrondo G, Ayrolles A, Antoun S, Caparos S, Catalán A, Ellul P, Dobrosavljevic M, Farhat LC, Fico G, Eudave L, Groenman AP, Højlund M, Jurek L, Nourredine M, Oliva V, Parlatini V, Psyllou C, Salazar-de-Pablo G, Tomlinson A, Westwood SJ, Cipriani A, Correll CU, Yon DK, Larsson H, Ostinelli EG, Shin JI, Fusar-Poli P, Ioannidis JPA, Radua J, Solmi M, Delorme R, Cortese S**  
Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making.  
BMJ. 2025 Nov 26;391:e085875. doi: 10.1136/bmj-2025-085875.

PMID: 41297970. IF 55.1

97. **Gredner T, von Terzi P, Erbas B, Wodarz N, Pogarell O**  
Nitazene: Neue synthetische Opioide als wachsende Bedrohung und die Rolle von Monitoring.  
Suchtmed 2025;27(5): 317-334. IF -
98. **Greil W, de Bardeci M, Nievergelt N, Erfurth A, Hasler G, Bridler R, Toto S, Grohmann R, Seifert J, Schoetsanitis G**  
Twenty-four years of prescription patterns in bipolar disorder inpatients with vs without lithium: a pharmacoepidemiological analysis of 8,707 cases in German-speaking countries.  
Int J Bipolar Disord. 2025 Feb 13;13(1):3. doi: 10.1186/s40345-025-00370-1.  
PMID: 39945975. IF 4.5
99. **Greiner SK, Pons MD, Ablimit A, Brauße E, Adorjan K, Budde M, Heilbronner M, Heilbronner U, Kalman JL, Navarro-Flores A, Kohshour MO, Reich-Erkelenz D, Schulte EC, Vogl T, Andlauer T, Anghelescu IG, Arolt V, Baune BT, Dannlowski U, Degenhardt F, Dietrich DE, Fallgatter AJ, Figge C, Forstner A, Jäger M, Juckel G, Konrad C, Nöthen MM, Lang FU, Reimer J, Reinighaus EZ, Rietschel M, Schmauß M, Schmitt A, Senner S, Spitzer C, Wiltfang J, Witt SH, Zimmermann J, Hasan A, Falkai P, Schulze TG, Papiol S, Senner F**  
How childhood adversities shape minds and lives: An analysis across the affective-to-psychotic spectrum.  
Psychiatry Res. 2025 Aug;350:116536. doi: 10.1016/j.psychres.2025.116536.  
PMID: 40424647. IF 5.1
100. **Haag L, Lancini E, Yakupov R, Ziegler G, Yi YJ, Lüsebrink F, Glanz W, Peters O, Spruth EJ, Altenstein S, Priller J, Schneider LS, Wang X, Preis L, Brosseron F, Roy-Kluth N, Fliessbach K, Wagner M, Wolfsgruber S, Kleineidam L, Ramirez A, Spottke A, Jessen F, Wiltfang J, Schneider A, Hansen N, Rostamzadeh A, Buerger K, Ewers M, Perneczky R, Janowitz D, Rauchmann BS, Teipel S, Kilimann I, Goerss D, Laske C, Munk MH, Heneka M, Dechent P, Hetzer S, Scheffler K, Düzel E, Betts MJ, Hämmerer D**  
CSF biomarkers are differentially linked to brain areas high and low in noradrenaline, dopamine and serotonin across the Alzheimer's disease spectrum.  
Brain Commun. 2025 Jan 23;7(1):fcf031. doi: 10.1093/braincomms/fcaf031.  
eCollection 2025. PMID: 39926613. IF 4.5
101. **Haas C, Klein L, Heckl M, Kesić M, Rueß AK, Gensichen J, Lukaschek K, Kruse T; POKAL-Group**  
Efficient Online Recruitment of Patients With Depressive Symptoms Using Social Media: Cross-Sectional Observational Study.  
JMIR Ment Health. 2025 Jun 3;12:e65920. doi: 10.2196/65920. PMID: 40460433.  
IF 7.4
102. **Haeckert J, Roeh A, Karch S, Koeglsperger T, Hasan A, Papazova I**  
Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation.  
Pharmacopsychiatry. 2025 Jan;58(1):5-13. doi: 10.1055/a-2446-6877.  
PMID: 39572152. IF 2.3

103. **Hahn L, Raabe FJ, Keeser D, Vetter C, Fanning J, Hasan A, Papzova I, Wiegand A, Falkai P, Meisenzahl E, Koutsouleris N**  
Mapping Neurochemical Signatures onto Brain Structure for Neurotransmitter-Informed Discrimination of Schizophrenia Patients from Healthy Controls.  
medRxiv [Preprint]. 2025 Dec 4;2025.12.04.25341533. doi: 10.64898/2025.12.04.25341533 .PMID: 41404274
  
104. **Harms MP, Cho KK, Anticevic A, Bolo NR, Bouix S, Campbell D, Cannon TD, Cecchi G, Goncalves M, Haidar A, Hughes DE, Izyurov I, John O, Kapur T, Kim N, Kotler E, Kubicki M, Kuperman JM, Laulette K, Lindberg U, Markiewicz C, Ning L, Poldrack RA, Rath Y, Romo PA 3rd, Tamayo Z, Wannan C, Wickham A, Yassin W, Zhou JH, Addington J, Alameda L, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Diaz-Caneja CM, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Mathalon DH, Mittal VA, Nordentoft M, Pearlson GD, Perez J, Perkins DO, Powers AR 3rd, Rogers J, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Thompson JL, Upthegrove R, Verma SK, Wang J, Wolf DH, Kahn RS, Kane JM, McGorry PD, Nelson B, Woods SW, Shenton ME, Wood SJ, Bearden CE; Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ); Pasternak O**  
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.  
Schizophrenia (Heidelb). 2025 Apr 2;11(1):52. doi: 10.1038/s41537-025-00581-6. PMID: 40175382. IF 4.5
  
105. **Hasanaj G, Jaeger I, Karsli B, Schulz E, Boudriot E, Roell L, Korman M, Kallweit MS, Dengl F, Klimas N, Fischer K, Hanken K, Meisinger V, Moussiopoulou J, Yakimov V, Karch S, Hasan A, Schmitt A, Falkai P; CDP Working Group; Pogarell O, Raabe FJ, Wagner E, Mortazavi M, Keeser D**  
Periodic and Aperiodic Alterations of Resting-State EEG in Schizophrenia Spectrum Disorders: Cognitive and Clinical Insights.  
Eur J Neurosci. 2025 Oct;62(7):e70263. doi: 10.1111/ejn.70263. PMID: 41045101. IF 2.5
  
106. **Herwig U, Schnell K, Daumann J, Jungaberle A, Koller G, Mertens LJ, Borgwardt S**  
[Psychedelics in psychiatry: an open debate].  
Fortschr Neurol Psychiatr. 2025 Sep;93(9):343-351. doi: 10.1055/a-2453-0910. PMID: 39667389. IF 0.5
  
107. **Hilleke M, Lang T, Helbig-Lang S, Alpers GW, Arolt V, Deckert J, Fydrich T, Hamm AO, Kircher T, Richter J, Ströhle A, Wittchen HU, Gerlach AL**  
How Do Patients' Fear Prediction and Fear Experience Impact Exposure-Based Therapy for Panic Disorder With Agoraphobia? A Comprehensive Analysis of Fear Prediction.  
Depress Anxiety. 2025 Jun 18;2025:6963860. doi: 10.1155/da/6963860. eCollection 2025. PMID: 40567829. IF 2.7
  
108. **Hoch E, Hämmig R, Preuss U**  
Cannabis und Cannabinoide.  
In: Soyka M, Batra A, Moggi F, Walter M (Hrsg)  
Suchtmedizin, Elsevier, 2. Auflage 2025, S. 193-207.

109. **Hoch E, Hall W, Feingold D**  
Cannabis use in Europe.  
Eur Arch Psychiatry Clin Neurosci. 2025 Mar;275(2):277-279.  
doi: 10.1007/s00406-025-01972-7. PMID: 39951121. IF 3.9
110. **Hoch E, Krowartz EM, Hollweck R, Möckl J, Olderbak S**  
Cannabis Consumption Before and After Partial Legalization in Germany: Early Trends, Consumption Patterns, and Motives.  
Dtsch Arztebl Int. 2025 Nov 14;122(23):632-637. doi: 10.3238/arztebl.m2025.0161. PMID: 40959988. IF 8.7
111. **Hoch E, Murawski M, Ferri M, Feingold D**  
Cannabis use disorder: an overview of treatment approaches in Europe.  
Eur Arch Psychiatry Clin Neurosci. 2025 Mar;275(2):315-326. doi: 10.1007/s00406-025-01964-7. PMID: 40035833. IF 3.9
112. **Hoch E, Volkow ND, Friemel CM, Lorenzetti V, Freeman TP, Hall W**  
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.  
Eur Arch Psychiatry Clin Neurosci. 2025 Mar;275(2):281-292.  
doi: 10.1007/s00406-024-01880-2. PMID: 39299947. IF 3.9
113. **Hofer EM, Musil R, Strupp L, Falkai P, Strupp M, Schindlbeck KA**  
Tourette syndrome: effects of acetyl-leucine in two individuals.  
J Neurol. 2025 May 19;272(6):408. doi: 10.1007/s00415-025-13136-7. PMID: 40387962. IF 5.4
114. **Højlund M, Kafali HY, Kırmızı B, Fusar-Poli P, Correll CU, Cortese S, Sabé M, Fiedorowicz J, Saraf G, Zein J, Berk M, Husain MI, Rosenblat JD, Rubaiyat R, Corace K, Wong S, Hatcher S, Kaluzienski M, Yatham LN, Cipriani A, Gosling CJ, Carhart-Harris R, Tanuseputro P, Myran DT, Fabiano N, Moher D, Mayo LM, Nicholls SG, White T, Prisco M, Radua J, Vieta E, Ladha KS, Katz J, Veroniki AA, Solmi M**  
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.  
Eur Neuropsychopharmacol. 2025 Dec;101:41-55. doi: 10.1016/j.euroneuro.2025.09.011. PMID: 41205366. IF 8.1
115. **Howes OD, Bukala BR, Chen EYH, Correll CU, Hasan A, Honer WG, Kane JM, Leucht S, Sifakis S, Agid O, Akena D, Arango C, Atwoli L, Barnes TRE, Birnbaum ML, Bitter I, Breier A, Buchanan RW, Citrome L, Cotter DR, Crossley N, Davidson M, de Bartolomeis A, DeLisi LE, Dollfus S, Dursun SM, Ebdrup BH, Elkis H, Emsley R, Falkai P, Fernández-Egea E, Fleischhacker W, Freudenreich O, Gadelha A, Gaebel W, Graff-Guerrero A, Gridley A, Hallak JEC, Homan P, Kahn RS, Kaiser S, Kapi M, Kennedy JL, Kim E, Kinon BJ, Soo Kwon J, Lawrie SM, Lee J, Leweke FM, Li T, Libiger J, Marder SR, Melle I, Meltzer H, Mucci A, Naber D, Nakajima S, Nielsen J, O'Brien O, Ojagbemi A, Omlor W, Pantelis C, Peuskens J, Raedler TJ, Ran MS, Marques TR, Remington G, Rossell S, Rubio JM, Sachs G, Scott J, Si T, Siskind D, Siu CO, Sommer IE, Suzuki T, Takeuchi H, Tandon R, Taylor D, Teferra S, Thomas N, Tihihonen J, Uchida H, Uçok A, Umbricht D, Venkatasubramanian G, Wagner E, Walters JTR, Wang C, Weiser M, Wright C, Yu X, McCutcheon RA**  
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.  
Am J Psychiatry. 2025 Nov 1;182(11):969-983. doi: 10.1176/appi.ajp.20241040. PMID: 41058236. IF 15.9

116. **Hubert J, Schmidt V, Wittmann E, Melder A, Lomidze A, Smit N, Bulubas L, Campana M, Vogelmann U, Dornheim B, Padberg F, Heinen F, Landgraf MN**  
Transcranial magnetic stimulation in children with fetal alcohol spectrum disorder: A randomised, crossover pilot-trial.  
Eur J Paediatr Neurol. 2025 Mar;55:111-120. doi: 10.1016/j.ejpn.2025.03.013.  
PMID: 40203488. IF 2.9
117. **Jebrini T, Ruzicka M, Stubbe H, Adorjan K**  
Post COVID-19 conditions and neurocognitive impairment – current findings and clinical implications.  
Clin Transl Neurosci 2025; 9(2): 25. IF 2.0
118. **Jebrini T, Ruzicka M, Völk F, Fonseca GJI, Pernpruner A, Benesch C, Valdinoci E, von Baum M, Weigl M, Subklewe M, von Bergwelt-Baildon M, Roeder J, Mayerle J, Heindl B, Adorjan K, Stubbe HC**  
Predicting work ability impairment in post COVID-19 patients: a machine learning model based on clinical parameters.  
Infection. 2025 Jun;53(3):1189-1197. doi: 10.1007/s15010-024-02459-8.  
PMID: 39821741. IF 3.9
119. **Jebrini T, Stubbe HC, Ruzicka M, Adorjan K**  
Neurocognitive challenges Post-COVID: current perspectives and future solutions.  
Eur Arch Psychiatry Clin Neurosci. 2025 Feb;275(1):1-3. doi: 10.1007/s00406-025-01962-9. PMID: 39853360. IF 3.9
120. **Jessen F, Arbizu J, Boada M, Balasa M, Bennys K, Boban M, Bürger K, Chincarini A, Cagnin A, De Deyn PP, Düzel E, Engelborghs S, Ewers M, Exalto LG, van der Flier WM, Fortea J, Frederiksen KS, Frisoni GB, Frölich L, Garza-Martinez AJ, Grimmer T, Hanseeuw B, Hort J, Ivanoiu A, Kehoe PG, Kennelly SP, Kern S, Klöppel S, Krajčovičová L, Kramberger MG, McGuinness B, Mecocci P, Oberstein TJ, Ousset PJ, Paquet C, Perneczky R, Piazza F, Plantone D, Rainero I, Sacco G, Salmon E, Santana I, Scarmeas N, Schneider A, Schott JM, Solje E, Stefanova E, Stögmänn E, Strauss M, Sutovsky S, Waldemar G, Winblad B**  
Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer's disease.  
J Prev Alzheimers Dis. 2025 Sep;12(8):100259. doi: 10.1016/j.tjpad.2025.100259.  
PMID: 40640062. IF 6.7
121. **Kagerer-Volk S, Soyka M**  
Störungen durch Substanzgebrauch.  
In: Brunner A, Graw M, Laux G (Hrsg)  
Fahreignung bei psychischen Erkrankungen.  
MWV Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2025,  
2. Auflage S. 71-86.
122. **Kaji S, Berghoff SA, Spieth L, Schlaphoff L, Sasmita AO, Vitale S, Büschgens L, Kedia S, Zirngibl M, Nazarenko T, Damkou A, Hosang L, Depp C, Kamp F, Scholz P, Ewers D, Giera M, Ischebeck T, Wurst W, Wefers B, Schifferer M, Willem M, Nave KA, Haass C, Arzberger T, Jäkel S, Wirths O, Saher G, Simons M**  
Apolipoprotein E aggregation in microglia initiates Alzheimer's disease pathology by seeding  $\beta$ -amyloidosis.  
Immunity. 2025 Jan 14;58(1):263. doi: 10.1016/j.immuni.2024.11.024.  
PMID: 39637851. IF 30.6

123. **Kaleck T, Campos-Martin R, Cano A, Fernández MV, Martino-Adami P, Kleineidam L, Fuentes VMA, Tripathi KP, Parveen K, Puerta R, de Rojas I, Ravichandran KA, Peters O, Hellmann-Regen J, Priller J, Gemenetzi M, Schneider A, Wiltfang J, Düzel E, Buerger K, Perneczky R, Teipel S, Laske C, Brosseon F, Marquié M, van den Hove D, Boada M, Heneka MT, Wagner M, Marchant N, Lambert JC, Frikke-Schmidt R, Jessen F, Ruiz A, Ramirez A**  
Replication of blood DNA methylomic signatures associated with cerebrospinal fluid levels of YKL-40 and NfL biomarkers.  
Alzheimers Dement. 2025 Sep;21(9):e70647. doi: 10.1002/alz.70647.  
PMID: 40898416. IF 12.8
  
124. **Kambeitz J, Hacker H, Hoheisel L, Buciuman M, Böke A, Lichtenstein T, Rosen M, Haas S, Ruef A, Dwyer D, Brambilla P, Bonivento C, Upthegrove R, Wood S, Borgwardt S, Meisenzahl E, Ruhrmann S, Salokangas R, Dannlowski U, Koutsouleris N, Kambeitz-Illankovic L, Lencer R**  
Disrupted Hierarchical Functional Brain Organization in Affective and Psychotic Disorders: Insights from Functional Brain Gradients.  
Res Sq [Preprint]. 2025 Apr 17;rs.3.rs-6287335. doi: 10.21203/rs.3.rs-6287335/v1.  
PMID: 40321774
  
125. **Kambeitz-Illankovic L, Strube W, Baune BT, Falkai P, Röhl L, Leucht S**  
[Cognitive impairments associated with schizophrenic psychoses : Diagnostics, course and therapy].  
Nervenarzt. 2025 Sep;96(5):482-489. doi: 10.1007/s00115-024-01773-8.  
PMID: 39589503. IF 1.1
  
126. **Karcher S, Gertzen M, Rosenberger C, Schwarz J, Villa, PI, Strasburger, M, Rabenstein A, Pogarell O, Martl P, Hentschel H, Horstmann A, Silva-Leao D, Rüther T**  
When Stigma Meets the Sheets: Sexual Satisfaction, LGB Identity, and Shame Proneness in LGB Individuals-A Quantitative Study.  
Sexuality Research and Social Policy 2025, June 19, open access. IF 2.8
  
127. **Kas MJH, Penninx BWJH, Knudsen GM, Cuthbert B, Falkai P, Sachs GS, Ressler KJ, Bałkowiec-Iskra E, Butlen-Ducuing F, Leboyer M, Marston H, Luthman J, Mantua V**  
Precision psychiatry roadmap: towards a biology-informed framework for mental disorders.  
Mol Psychiatry. 2025 Aug;30(8):3846-3855. doi: 10.1038/s41380-025-03070-5.  
PMID: 40533548. IF 10.4
  
128. **Kasper S, Volz HP, Möller HJ, Schläfke S, Klement S, Anghelescu IG, Seifritz E**  
Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial.  
Eur Arch Psychiatry Clin Neurosci. 2025 Sep;275(6):1693-1703.  
doi: 10.1007/s00406-024-01783-2. PMID: 38558147. IF 3.9
  
129. **Keefe RSE, Harvey PD, Correll CU, Falkai P, Hashimoto N, Klein H, Krystal JH, Marder S, Medalia A, Sumiyoshi T, Wang G, Zhang H, Blahova Z, Bichard-Sall I, English BA, Fu E, Gruenenfelder F, Groeschl M, Kimura K, Tang W, von der Goltz C, Fowler C**  
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials.  
Lancet Psychiatry. 2025 Dec;12(12):906-920.  
doi: 10.1016/S2215-0366(25)00296-2. PMID: 41233083. IF 21.1

130. **Kemna S, Bringmann M, Karnouk C, Hoell A, Tschorn M, Kamp-Becker I, Padberg F, Übleis A, Hasan A, Falkai P, Salize HJ, Meyer-Lindenberg A, Banaschewski T, Schneider F, Habel U, Plener P, Hahn E, Wiechers M, Strupf M, Jobst A, Millenet S, Hoehne E, Sukale T, Schuster M, Dinauer R, Mehran N, Kaiser F, Lieb K, Heinz A, Rapp M, Bajbouj M, Böge K**  
Characterizing of dropouts in the mental health of refugees and asylum seekers (MEHIRA) study examining the effects of a stepped and collaborative care model - a multicentered rater-blinded randomized controlled trial - CORRIGENDUM. Psychol Med. 2025 Mar 24;55:e95. doi: 10.1017/S0033291725000170. PMID: 40125777. IF -
131. **Kemna S, Bringmann M, Karnouk C, Hoell A, Tschorn M, Kamp-Becker I, Padberg F, Übleis A, Hasan A, Falkai P, Salize HJ, Meyer-Lindenberg A, Banaschewski T, Schneider F, Habel U, Plener P, Hahn E, Wiechers M, Strupf M, Jobst A, Millenet S, Hoehne E, Sukale T, Schuster M, Dinauer R, Mehran N, Kaiser F, Lieb K, Heinz A, Rapp M, Bajbouj M, Böge K**  
Predictors of symptom change in the mental health of refugees and asylum seekers (MEHIRA) study examining the effects of a stepped and collaborative care model - A multicentered rater-blinded randomized controlled trial. J Affect Disord. 2025 Feb 1;370:45-53. doi: 10.1016/j.jad.2024.10.103. PMID: 39490423. IF 5.7
132. **Khuntia A, Buciuman MO, Fanning J, Stolicyn A, Vetter C, Armio RL, From T, Goffi F, Hahn L, Kaufmann T, Laurikainen H, Maggioni E, Martinez-Zalacain I, Ruef A, Dong MS, Schwarz E, Squarcina L, Andreassen O, Bellani M, Brambilla P, Haren NV, Hietala J, Lawrie SM, Soriano-Mas C, Whalley H, Taquet M, Meisenzahl E, Falkai P, Wiegand A, Koutsouleris N; ECNP Neuroimaging Network**  
Towards collaborative data science in mental health research: The ECNP neuroimaging network accessible data repository. Neurosci Appl. 2025 Dec 9;4:105407. doi: 10.1016/j.nsa.2024.105407. eCollection 2025. PMID: 40654593. IF 3.0
133. **Khuntia A, Popovic D, Sarisik E, Buciuman MO, Pedersen ML, Westlye LT, Andreassen OA, Meyer-Lindenberg A, Kambeitz J, Salokangas RKR, Hietala J, Bertolino A, Borgwardt S, Brambilla P, Upthegrove R, Wood SJ, Lencer R, Meisenzahl E, Falkai P, Schwarz E, Wiegand A, Koutsouleris N**  
The BMlgap tool to quantify transdiagnostic brain signatures of current and future weight. Nat Ment Health. 2025;3(11):1395-1406. doi: 10.1038/s44220-025-00522-3. PMID: 41211531. IF 9.3
134. **Kiefer F, Hoch E, Gouzoulis-Mayrank E**  
How should politicians deal with the legalization of cannabis in the last legislative period? Sucht 2025; 71(4): 205-207. IF 0.8
135. **Koepl KL, Wambsganz A, Roell L, Schwaiger R, Fischer T, Falkai P, Hasan A, Schmitt A, Maurus I**  
Determinants of physical activity and exercise in individuals with mental illness: results from a large cross-sectional online survey. BMJ Open. 2025 Jun 8;15(6):e092862. doi: 10.1136/bmjopen-2024-092862. PMID: 40484426. IF 2.5

136. **Kösters M, Allgöwer A, Becker T, Kilian R, Gühne U, Riedel-Heller S, Hasan A, Falkai P, Ajayi K, Brieger P, Frasch K, Halms T, Heres S, Jäger M, Küthmann A, Putzhammer A, Schneeweiß B, Schwarz M, Breilmann J**  
Implementation of a patient-focused psychosocial intervention guideline for people with severe mental illness: Cluster-randomised controlled trial.  
Eur Psychiatry. 2025 Oct 23;68(1):e163. doi: 10.1192/j.eurpsy.2025.10126.  
PMID: 41126666. IF 7.9
137. **Kolar DR, Haynos AF, Wang SB, Lask T, Murray SB, Voderholzer U, Gorrell S**  
Identification of Affective- and Social-Reinforcement Functions of Driven Exercise: Evidence From Three Samples.  
Clin Psychol Sci. 2025 May;13(3):582-597. doi: 10.1177/21677026241290455.  
PMID: 40453355. IF 5.1
138. **Koriath CAM, Guntoro F, Norsworthy P, Dolzhenko E, Eberle M, Hensman Moss DJ, Flower M, Hummerich H, Rosser AE, Tabrizi SJ, Mead S, Wild EJ**  
Huntington's disease phenocopy syndromes revisited: a clinical comparison and next-generation sequencing exploration.  
J Neurol Neurosurg Psychiatry. 2025 Apr 10;96(5):466-469.  
doi: 10.1136/jnnp-2024-333602. PMID: 39443079. IF 7.7
139. **Koriath CAM, Kurz C, Mead S, Wild EJ, Tabrizi SJ**  
Decoding Huntington's disease: a global survey on symptoms and genetic testing practices.  
Eur Arch Psychiatry Clin Neurosci. 2025 Dec;275(8):2557-2561.  
doi: 10.1007/s00406-025-02042-8. PMID: 40560365. IF 3.9
140. **Koriath CA, Perneczky R**  
Obesity and Alzheimer's disease dementia: Examining inflammatory links to cognitive decline and neuropsychiatric symptoms.  
J Alzheimers Dis. 2025 Jul;106(1):51-53. doi: 10.1177/13872877251338467.  
PMID: 40329584. IF 3.4
141. **Koriath CAM, Rauchmann B, Schoeberl F, Zwergal A, Falkai P, Perneczky R**  
Vestibular dysfunction: a hidden risk factor for Alzheimer's disease.  
J Neurol. 2025 Mar 25;272(4):285. doi: 10.1007/s00415-025-13045-9.  
PMID: 40131480. IF 5.4
142. **Koummati M, Vrublevska J, De Hert M, Young AH, Fusar-Poli P, Tandon R, Javed A, Fountoulakis KN**  
Attenuated mental symptoms in the general population: first data from the observational cross-sectional ATTENTION study in Greece.  
CNS Spectr. 2025 Feb 19;30(1):e27. doi: 10.1017/S1092852925000112.  
PMID: 39969046. IF 4.6
143. **Koutsouleris N, Buciuman MO, Vetter C, Bajrić A, Weyer C, Perdomo ST, Khuntia AT, Milaneschi Y, Popovic D, Dwyer D, Chisholm K, Kambeitz-Ilankovic L, Antonucci L, Lichtenstein T, Rosen M, Ruhrmann S, Kambeitz J, Riecher-Rössler A, Upthegrove R, Salokangas R, Hietala J, Pantelis C, Lencer R, Meisenzahl E, Wood S, Brambilla P, Borgwardt S, Bertolino A, Falkai P**  
Multimodal biological profiles of symptom-based subgroups in recent-onset psychosis.  
Res Sq [Preprint]. 2025 Oct 30:rs.3.rs-7867983. doi: 10.21203/rs.3.rs-7867983/v1.  
PMID: 41282156. IF -

144. **Kramer J, Koller G, Pogarell O**  
Psychiatrische Risiken bei der Therapie mit Cannabinoiden.  
Schmerzmedizin 2025; 41: 8-13. IF -
145. **Krystkiewicz M, Soyka M**  
Suicide Risk in Alcohol Use Disorders: Literature Review and Study Protocol with Preliminary Data for a Study in Treatment-Seeking Inpatients.  
Healthcare (Basel). 2025 Feb 28;13(5):535. doi: 10.3390/healthcare13050535. PMID: 40077097. IF 3.4
146. **Kuang HJ, Yang HS, Feng YX, Tang H, Fan Q, Xu YQ, Cui S, Musil R, Luxenburger H, Zhang YX, Zhao H, Zhang YQ**  
Efficacy and safety of acupuncture therapies for adult patients with mild and moderate major depressive disorder: A systematic review and meta-analysis.  
J Integr Med. 2025 Sep;23(5):471-491. doi: 10.1016/j.joim.2025.06.008. PMID: 40744847. IF 5.2
147. **Kuchler T, Günthner R, Ribeiro A, Hausinger R, Streese L, Wöhl A, Kessler V, Negele J, Assali T, Carbajo-Lozoya J, Lech M, Schneider H, Adorjan K, Stubbe HC, Hanssen H, Kotliar K, Haller B, Heemann U, Schmaderer C**  
Correction: Persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation.  
Angiogenesis. 2025 Oct 10;28(4):54. doi: 10.1007/s10456-025-10007-7. PMID: 41071367. IF -
148. **Kuhn E, Klinger HM, Amariglio RE, Wagner M, Jessen F, Düzel E, Heneka MT, Chételat G, Rentz DM, Sperling RA, Ebenau JL, Butterbrod E, Van Der Flier WM, Sikkes SAM, Teunissen CE, Van Harten AC, Van De Giessen EM, Rami L, Tort A, Sánchez Benavides G, Gifford KA, Van Hulle C, Buckley RF; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle flagship study of ageing, A4 Study Team; DELCODE Study; Harvard Aging Brain Study**  
SCD-plus features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies.  
Alzheimers Dement. 2025 May;21(5):e14307. doi: 10.1002/alz.14307. PMID: 39985404. IF 12.8
149. **Kurz C, Carli L, Gürsel SÜ, Schrurs I, Jethwa A, Carboni M, Bittner T, Hortsch S, Keiser D, Brendel M, Burow L, Haeckert J, Koriath CAM, Tatò M, Utecht J, Papazov B, Morenas-Rodriguez E, Pogarell O, Palleis C, Weidinger E, Stoecklein S, Levin J, Höglinger G, Rauchmann BS, Perneczky R**  
Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer's disease and corticobasal syndrome.  
Eur Arch Psychiatry Clin Neurosci. 2025 Dec;275(8):2255-2273. doi: 10.1007/s00406-025-02013-z. PMID: 40314736. IF 3.9
150. **Kurz CI, Endres B, Hufnagel A, Tegethoff P, Perneczky R**  
["Cannot focus" - differential diagnosis].  
MMW Fortschr Med. 2025 Mar;167(4):45-49. doi: 10.1007/s15006-025-4663-7. PMID: 40050599. IF -

151. **La-Torraca-Vittori P, Tarchi L, Arrigo E, Lanterna S, Tosi E, Doose A, Palesi F, Pischedda D, Ricca V, Fusar-Poli P, Damiani S**  
Knocking at the Doors of Perception: Relating LSD Effects on Low-Frequency Fluctuations and Regional Homogeneity to Receptor Densities in fMRI.  
Eur J Neurosci. 2025 Nov;62(10):e70338. doi: 10.1111/ejn.70338.  
PMID: 41305961. IF 2.5
152. **Lammi V, Nakanishi T, Jones SE, Andrews SJ, Karjalainen J, Cortés B, O'Brien HE, Ochoa-Guzman A, Fulton-Howard BE, Broberg M, Haapaniemi HH, Kanai M, Pirinen M, Schmidt A, Mitchell RE, Mousas A, Mangino M, Huerta-Chagoya A, Sinnott-Armstrong N, Cirulli ET, Vaudel M, Kwong ASF, Maiti AK, Marttila MM, Posner DC, Rodriguez AA, Batini C, Minnai F, Dearman AR, Warmerdam CAR, Sequeros CB, Winkler TW, Jordan DM, Rešcenko R, Miano L, Lane JM, Chung RK, Guillen-Guio B, Leavy OC, Carvajal-Silva L, Aguilar-Valdés K, Frangione E, Guare L, Vergasova E, Marouli E, Striano P, Zainulabid UA, Kumar A, Ahmad HF, Edahiro R, Azekawa S; Long COVID Host Genetics Initiative; FinnGen; VA Million Veteran Program; MexGen-COVID Initiative; DBDS Genomic Consortium; GEN-COVID Multicenter Study; PHOSP-COVID Collaborative Group; GENCOV Study; Estonian Biobank Research Team; Luoh SW, Erikstrup C, Pedersen OBV, Lerner-Ellis J, Colombo A, Grzyski JJ, Ishii M, Okada Y, Beckmann ND, Kumari M, Wagner R, Heid IM, John C, Short PJ, Magnus P, Ansone L, Valenti LVC, Lee SA, Wain LV, Verdugo RA, Banasik K, Geller F, Franke LH, Rakitko A, Duncan EL, Renieri A, Tsilidis KK, de Cid R, Niavarani A, Abner E, Tusié-Luna T, Ver...See abstract for full author list →**  
Genome-wide association study of long COVID.  
Nat Genet. 2025 Jun;57(6):1402-1417. doi: 10.1038/s41588-025-02100-w.  
PMID: 40399555. IF 25.5
153. **Lamp N, Breilmann J, Becker T, Allgöwer A, Kilian R, Gühne U, Riedel-Heller SG, Hasan A, Falkai P, Ajayi K, Brieger P, Frasch K, Heres S, Jäger M, Küthmann A, Putzhammer A, Schneeweiß B, Schwarz M, Kösters M**  
[Housing Situation of People with Severe Mental Illnesses].  
Psychiatr Prax. 2025 Mar;52(2):80-88. doi: 10.1055/a-2419-7254.  
PMID: 39515373. IF 0.9
154. **Lange M, Gogarty E, Martyn M, Braude P, Fayez F, Koutsouleris N, Howes O, Twumasi R, Carter B**  
An accessible, timely method for identifying medications for repurposing: hypothesis generating; testing and validation.  
BMC Digital Health 2025; 3: 30. IF 3.2
155. **Lange M, Mehta U, Koutsouleris N, Fayez F, Twumasi R**  
Developing and validating a machine learning pharmaceutical therapy recommender system for US-based hospital in-patients with schizophrenia spectrum disorders.  
BMC Psychiatry. 2025 Dec 1;26(1):10. doi: 10.1186/s12888-025-07657-8.  
PMID: 41327062. IF 4.6

156. **Langhammer T, Hilbert K, Adolph D, Arolt V, Bischoff S, Böhnlein J, Cwik JC, Dannlowski U, Deckert J, Domschke K, Evens R, Fydrich T, Gathmann B, Hamm AO, Heinig I, Herrmann MJ, Hollandt M, Junghoefer M, Kircher T, Koelkebeck K, Leehr EJ, Lotze M, Margraf J, Mumm JLM, Pittig A, Plag J, Richter J, Roesmann K, Ridderbusch IC, Schneider S, Schwarzmeier H, Seeger F, Siminski N, Straube T, Ströhle A, Szeska C, Wittchen HU, Wroblewski A, Yang Y, Straube B, Lueken U**  
Resting-state functional connectivity in anxiety disorders: a multicenter fMRI study.  
Mol Psychiatry. 2025 Apr;30(4):1548-1557. doi: 10.1038/s41380-024-02768-2. PMID: 39367057. IF 10.4
157. **Larsen AJ, Teobaldi G, Espinoza Jeraldo RI, Falkai P, Cooper C**  
Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: a systematic review and meta-analysis.  
BMJ Ment Health. 2025 Mar 3;28(1):e301324.  
doi: 10.1136/bmjment-2024-301324. PMID: 40032553. IF 6.6
158. **Laux G, Brunnauer A**  
Einleitung und Epidemiologie.  
In: Brunnauer A, Graw M, Laux G (Hrsg)  
Fahreignung bei psychischen Erkrankungen.  
MWV Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2025,  
2. Auflage S. 7-15
159. **Laux G, Brunnauer A**  
Psychopharmaka.  
In: Brunnauer A, Graw M, Laux G (Hrsg)  
Fahreignung bei psychischen Erkrankungen.  
MWV Medizinisch Wissenschaftliche Verlagsgesellschaft, Berlin, 2025,  
2. Auflage S. 150-175.
160. **Lohner V, Perna L, Schöttker B, Perneczky R, Brenner H, Mons U**  
Associations of blood-based biomarkers of neurodegenerative diseases with mortality, cardio- and cerebrovascular events in persons with chronic coronary syndrome.  
Exp Gerontol. 2025 Feb;200:112684. doi: 10.1016/j.exger.2025.112684. PMID: 39824235. IF 5.1
161. **Lohner V, Perna L, Schöttker B, Perneczky R, Kliegel M, Brenner H, Mons U**  
Prospective associations of blood-based biomarkers of neurodegenerative diseases with cognitive performance in a cohort of patients with chronic coronary syndrome.  
J Alzheimers Dis. 2025 Dec;108(4):1507-1513. doi: 10.1177/13872877251389147. PMID: 41252287. IF 3.4
162. **Luethi MS, Borriore L, Cavendish BA, Aparicio LVM, Goerigk S, Ramos MRF, Moran NKS, Carneiro AM, Valiengo L, Moura DO, de Souza JP, Batista MP, da Silva VA, Klein I, Suen P, Gallucci-Neto J, Padberg F, Razza LB, Vanderhasselt MA, Lotufo PA, Bensenor IM, Fregni F, Brunoni AR**  
Effects of home-use transcranial direct current stimulation on clusters of depressive symptoms: an ancillary analysis of the PSYLECT study.  
Braz J Psychiatry. 2025 ;47:e20243972. doi: 10.47626/1516-4446-2024-3972. PMID: 40014805. IF 2.9

163. **Lutz APC, Arend AK, Voderholzer U, Vögele C, Blechert J**  
Interoceptive profiles of eating and weight disorders.  
Sci Rep. 2025 Dec 21;16(1):1045. doi: 10.1038/s41598-025-30683-1.  
PMID: 4142231. IF 4.9
164. **Ma W, Warnhoff I, Stephan M, Ma X, Dehne K, Volkmann P, Kannaiyan N, Brankatschk B, Jensen N, Rossner MJ, Scheuss V, Wehr MC**  
TAOK2 controls synaptic plasticity and anxiety via ERK and calcium signaling.  
iScience. 2025 Oct 9;28(11):113712. doi: 10.1016/j.isci.2025.113712.  
eCollection 2025 Nov 21. PMID: 41210984. IF 4.5
165. **Macchia A, Albantakis L, Zebhauser PT, Brandi ML, Schilbach L, Brem AK**  
Autistic Adults Avoid Unpredictability in Decision-Making.  
J Autism Dev Disord. 2025 Dec;55(12):4234-4246. doi: 10.1007/s10803-024-06503-2. PMID: 39158770. IF 2.6
166. **Madaria L, Aymerich C, Pedruzo B, Salazar de Pablo G, Alonso-Alconada D, Fusar-Poli P, Gonzalez-Torres MÁ, Catalan A**  
Allostatic load index across the psychosis spectrum: a systematic review and meta-analysis.  
Front Psychiatry. 2025 Jul 1;16:1590547. doi: 10.3389/fpsyt.2025.1590547.  
eCollection 2025. PMID: 40666432. IF 3.8
167. **Madaria L, Aymerich C, Pedruzo B, Salazar de Pablo G, Alonso-Alconada D, Fusar-Poli P, Gonzalez-Torres MÁ, Catalan A**  
Correction: Allostatic load index across the psychosis spectrum: a systematic review and meta-analysis.  
Front Psychiatry. 2025 Aug 8;16:1673042. doi: 10.3389/fpsyt.2025.1673042.  
eCollection 2025. PMID: 40859937. IF -
168. **Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Electronic address: andrew.mcintosh@ed.ac.uk; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium**  
Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies.  
Cell. 2025 Feb 6;188(3):640-652.e9. doi: 10.1016/j.cell.2024.12.002.  
PMID: 39814019. IF 45.1
169. **Mathalon DH, Nicholas S, Roach BJ, Billah T, Lavoie S, Whitford T, Hamilton HK, Addamo L, Anohkin A, Bekinschtein T, Belger A, Buccilli K, Cahill J, Carrión RE, Damiani S, Dzafic I, Ebdrup BH, Izyurov I, Jarcho J, Jenni R, Jo A, Kerins S, Lee C, Martin EA, Mayol-Troncso R, Niznikiewicz MA, Parvaz M, Pogarell O, Prieto-Montalvo J, Rabin R, Roalf DR, Rogers J, Salisbury DF, Shaik R, Shankman S, Stevens MC, Suen YN, Swann NC, Tang X, Thompson JL, Tso I, Wenzel J, Zhou JH, Addington J, Alameda L, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Castillo-Passi RI, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Diaz-Caneja CM, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilanovic L, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Mittal VA, Nordentoft M, Pearlson GD, Perez J, Perkins DO, Powers AR, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Upthegrove R, Verma SK, Wang J, Wolf DH, Zhang T, Bouix S, Pasternak O, Cho KK, Coleman MJ, Dwyer D, Nunez A, Tamayo Z, Wood SJ, Kahn RS, Kane JM, McGorry PD, Bearden CE, Nelson B, Woods SW, Shenton ME; Ac...**  
See abstract for full author list →  
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.

Schizophrenia (Heidelb). 2025 Jun 6;11(1):85. doi: 10.1038/s41537-025-00622-0 .  
PMID: 40480970. IF 4.5

170. **Matheson C, Soyka M, Hard B, Brousse G, Meyner S, Seibold C, Torrens M**  
Management of patients in an unstable phase of opioid use disorder: Challenges, goals, and emerging evidence on long-acting buprenorphine.  
Heroin Addict Relat Clin Probl 2025; 27: 24.  
<https://doi.org/10.62401/2531-4122-2025-24>. IF 0.6
171. **Maywald M, Pogarell O, Chrobok A, Levai S, Keeser D, Tschentscher N, Rauchmann BS, Stöcklein S, Ertl-Wagner B, Papazov B, Paolini M, Karch S**  
Diagnostics and Group Therapy in Patients with Persistent Postural-Perceptual Dizziness and Anxiety Disorder: Biomarkers and Neurofunctional Correlates of Underlying Treatment Effects.  
Diagnostics (Basel). 2025 Jul 8;15(14):1729. doi: 10.3390/diagnostics15141729.  
PMID: 40722479. IF 3.8
172. **Meinke C, Hornstein S, Schmidt J, Arolt V, Dannlowski U, Deckert J, Domschke K, Fehm L, Fydrich T, Gerlach AL, Hamm AO, Heinig I, Hoyer J, Kircher T, Koelkebeck K, Lang T, Margraf J, Neudeck P, Pauli P, Richter J, Rief W, Schneider S, Straube B, Ströhle A, Wittchen HU, Zwanzger P, Walter H, Lueken U, Pittig A, Hilbert K**  
Advancing the Personalized Advantage Index (PAI): a Systematic Review and Application in Two Large Multi-Site Samples in Anxiety Disorders - ERRATUM.  
Psychol Med. 2025 May 2;55:e135. doi: 10.1017/S0033291725000431.  
PMID: 40314167. IF -
173. **Mekonen Yimer T, Hoch E, Fischer B, Dawson D, Hall W**  
The adverse public health effects of non-medical cannabis legalisation in Canada and the USA.  
Lancet Public Health. 2025 Feb;10(2):e148-e159. doi: 10.1016/S2468-2667(24)00299-8. PMID: 39909688. IF 26.5
174. **Mena S, Coutts F, von Trott J, Ucur E, Vetter C, Kahn RR, Fleischhacker WW, Kane JM, Howes OD, Upthegrove R, Lalouis PA, Koutsouleris N**  
AI-based prediction of depression symptomatology in first-episode psychosis patients: insights from the EUFEST and RAISE-ETP clinical trials.  
Psychol Med. 2025 Jul 30;55:e221. doi: 10.1017/S0033291725100950.  
PMID: 40736066. IF 5.2
175. **Mengel D, Soter E, Ott JM, Wacker M, Leyva A, Peters O, Hellmann-Regen J, Schneider LS, Wang X, Priller J, Spruth E, Altenstein S, Schneider A, Fliessbach K, Wiltfang J, Hansen N, Rostamzadeh A, Düzel E, Glanz W, Incesoy EI, Buerger K, Janowitz D, Ewers M, Perneczky R, Rauchmann B, Teipel S, Kilimann I, Laske C, Sodenkamp S, Spottke A, Brustkern J, Brosseron F, Wagner M, Stark M, Kleineidam L, Shao K, Lüsebrink F, Yakupov R, Schmid M, Hetzer S, Dechent P, Scheffler K, Berron D, Jessen F, Synofzik M; DELCODE study group**  
Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer's disease.  
Mol Psychiatry. 2025 Jul;30(7):3150-3159. doi: 10.1038/s41380-025-03021-0.  
PMID: 40247130. IF 10.4

176. **Meule A, Dieffenbacher AL, Kolar DR, Voderholzer U**  
Weight Suppression, Binge Eating, and Purging as Predictors of Weight Gain During Inpatient Treatment in Persons With Bulimia Nervosa.  
Eur Eat Disord Rev. 2025 Sep;33(5):941-949. doi: 10.1002/erv.3197.  
PMID: 40195010. IF 3.2
177. **Meule A, Kolar DR, Voderholzer U**  
Predictors of Treatment Outcome in Persons With Anorexia Nervosa: On the Practice of Regressing Body Mass Index at the End of Treatment on Body Mass Index at Baseline.  
Int J Eat Disord. 2025 Jan;58(1):254-258. doi: 10.1002/eat.24324.  
PMID: 39530477. IF 4.7
178. **Meule A, Kroll D, Bönsch M, Schneeberger T, Jarosch I, Gloeckl R, Voderholzer U, Koczulla AR**  
Mental and physical health in persons receiving inpatient pulmonary rehabilitation treatment for post-COVID condition.  
PLoS One. 2025 Aug 26;20(8):e0330938. doi: 10.1371/journal.pone.0330938.  
eCollection 2025. PMID: 40857338. IF 2.8
179. **Meule A, Wuttke EP, Koerner T, Cuntz U, Voderholzer U**  
Treatment outcome in a specialized unit for adults with severe and extreme anorexia nervosa at one-year follow up.  
J Eat Disord. 2025 Aug 25;13(1):187. doi: 10.1186/s40337-025-01374-z.  
PMID: 40855346. IF 5.7
180. **Meule A, Zisler EM, Metzner MS, Voderholzer U, Kolar DR**  
Characteristics of and treatment outcome in inpatients with emetophobia and other specific phobias.  
J Psychiatr Res. 2025 Sep;189:285-290. doi: 10.1016/j.jpsychires.2025.06.028.  
PMID: 40543409. IF 3.6
181. **Meyer C, Niedermeier T, Feyen PLC, Strübing FL, Rauchmann BS, Karali K, Gentz J, Tillmann YE, Landgraf NF, Rumpf SL, Ochs K, Wind-Mark K, Biechele G, Wagner J, Guersel S, Kurz CI, Schweiger M, Prtvar D, Shi Y, Banati RB, Liu GJ, Middleton RJ, Mitteregger-Kretzschmar G, Perneczky R, Koeglsperger T, Neher JJ, Tahirovic S, Brendel M, Herms J, Paeger L**  
Early Locus Coeruleus noradrenergic axon loss drives olfactory dysfunction in Alzheimer's disease.  
Nat Commun. 2025 Aug 8;16(1):7338. doi: 10.1038/s41467-025-62500-8.  
PMID: 40781079. IF 18.1
182. **Minichino A, Davies C, Karpenko O, Christodoulou N, Ramalho R, Nandha S, Damiani S, Provenzani U, Esposito CM, Mensi MM, Borgatti R, Stefana A, McGuire P, Fusar-Poli P**  
Preventing psychosis in people at clinical high risk: an updated meta-analysis by the World Psychiatric Association Preventive Psychiatry section.  
Mol Psychiatry. 2025 Jun;30(6):2773-2782. doi: 10.1038/s41380-025-02902-8.  
PMID: 39953286. IF 10.4
183. **Misiak B, Karska J, Kowalski S, Courtet P, Volpe U, Schouler-Ocak M, Destoop M, Adorjan K, Kraxner F, Buwalda VJA, Campion J, Beezhold J, Falkai P, Dom G**  
Urban mental health: a position paper of the European psychiatric association.  
Eur Psychiatry. 2025 Sep 3;68(1):e127. doi: 10.1192/j.eurpsy.2025.10100.  
PMID: 40898403. IF 7.9

184. **Möller HJ, Rupprecht R, Reif A**  
Innovative pharmacological depression treatment.  
Eur Arch Psychiatry Clin Neurosci. 2025 Sep;275(6):1537-1538. doi:  
10.1007/s00406-025-02040-w. PMID: 40742437. IF 3.9
  
185. **Möller-Leimkühler AM**  
Digitale Gewalt - auch gesamtgesellschaftlich ein wachsendes Problem.  
In: Dinges M, Möller-Leimkühler AM (Hg). Gewalterfahrungen von Jungen  
und Männern und die Folgen für ihre Gesundheit.  
Psychosozial Verlag 2025, S. 151-154
  
186. **Möller-Leimkühler AM**  
Gesundheitliche Folgen der Gewalterfahrung für Jungen und Männer.  
In: Dinges M, Möller-Leimkühler AM (Hg).  
Gewalterfahrungen von Jungen und Männern und die Folgen für ihre Gesundheit.  
Psychosozial Verlag 2025, S. 249-262
  
187. **Möller-Leimkühler AM**  
Zum Zusammenhang von Gewalt und psychischen Störungen.  
In: Dinges M, Möller-Leimkühler AM (Hg). Gewalterfahrungen von Jungen  
und Männern und die Folgen für ihre Gesundheit.  
Psychosozial Verlag 2025, S. 51-61
  
188. **Möller-Leimkühler AM, Kasper S**  
Depression im Alter - Fokus Männer.  
Österreichische Ärztezeitung 21, 2025, 22-28.
  
189. **Montejo L, Sole B, Fico G, Kalman JL, Budde M, Heilbronner U, Oliva V,  
De Prisco M, Martin-Parra S, Ruiz A, Martinez-Aran A, Adorjan K, Falkai P,  
Heilbronner M, Kohshour MO, Reich-Erkelenz D, Schaupp SK, Schulte EC,  
Senner F, Vogl T, Anghelescu IG, Arolt V, Baune BT, Dannlowski U,  
Dietrich DE, Fallgatter AJ, Figge C, Juckel G, Konrad C, Reimer J,  
Reininghaus EZ, Schmauß M, Wiltfang J, Zimmermann J, Vieta E, Papiol S,  
Schulze TG, Torrent C**  
Contrasting genetic burdens for bipolar disorder: Early onset versus late onset in  
an older adult bipolar disorder sample.  
Eur Neuropsychopharmacol. 2025 Mar;92:29-37. doi:  
10.1016/j.euroneuro.2024.12.001. PMID: 39718074. IF 8.1
  
190. **Monteleone AM, Carfagno M, Meule A, Naab S, Cascino G, Voderholzer U,  
Kolar DR**  
Effects of Childhood Emotional Abuse on Treatment Outcome in Adolescent  
Inpatients With Anorexia Nervosa.  
Int J Eat Disord. 2025 Sep;58(9):1769-1776. doi: 10.1002/eat.24484.  
PMID: 40476338. IF 4.7
  
191. **Mortazavi M, Amon J, Jäger I, Hasanaj G, Aminifarsani Z, Fischer K, Gamer M;  
CDP Working Group; Hasan A, Keefe RSE, Sachs G, Falkai P, Keeser D,  
Raabe F, Wagner E**  
Assessment of the German Version of Brief Assessment of Cognition in  
Schizophrenia (BACS).  
Schizophr Res Cogn. 2025 Apr 30;41:100364. doi: 10.1016/j.scog.2025.100364.  
eCollection 2025 Sep. PMID: 40386123. IF 2.4

192. **Mortazavi M, Gerdes LA, Hizarci Ö, Kümpfel T, Anslinger K, Padberg F, Stöcklein S, Keeser D, Ertl-Wagner B**  
Corrigendum to "Impact of adult-onset multiple sclerosis on MRI-based intracranial volume: A study in clinically discordant monozygotic twins" [NeuroImage Clin. 42 (2024) 103597].  
Neuroimage Clin. 2025;45:103669. doi: 10.1016/j.nicl.2024.103669.  
PMID: 39278805. IF -
  
193. **Moussiopoulou J, Yakimov V, Roell L, Rauchmann BS, Toth H, Melcher J, Jäger I, Lutz I, Kallweit MS, Papazov B, Boudriot E, Seelos K, Dehsarvi A, Campana M, Raabe F, Maurus I, Löhrs L, Brendel M, Stöcklein S, Falkai P, Hasan A, Group CW, Franzmeier N, Keeser D, Wagner E**  
Higher blood-brain barrier leakage in schizophrenia-spectrum disorders: A comparative dynamic contrast-enhanced magnetic resonance imaging study with healthy controls.  
Brain Behav Immun. 2025 Aug;128:256-265. doi: 10.1016/j.bbi.2025.04.003.  
PMID: 40194748. IF 7.5
  
194. **Müller N**  
Immunological Approaches in the Diagnosis and Treatment of Psychiatric Disorders: A Historical Overview.  
Neuroimmunomodulation. 2025;32(1):16-23. doi: 10.1159/000542784.  
PMID: 39591951. IF 3.7
  
195. **Mukherjee K, Guest PC, Nussbaumer M, Dudeck L, Shokati Asl L, Meyer-Lotz G, Dobrowolny H, Borucki K, Bernstein HG, Link A, Relja B, Schiltz K, Nickl-Jockschat T, Steiner J**  
Assessment of intestinal barrier integrity and associations with innate immune activation and metabolic syndrome in acutely ill, antipsychotic-free schizophrenia patients.  
J Neuroinflammation. 2025 Oct 13;22(1):232. doi: 10.1186/s12974-025-03584-3.  
PMID: 41084047. IF 11.5
  
196. **Musil R**  
Traumaakupunktur im Team - Integrative Therapie in der akutpsychosomatischen Klinik.  
Deutsche Zeitschrift für Akupunktur 2025; 68(3): 164-167. IF -
  
197. **Mutschler J, Soyka M**  
Alkohol.  
In: Soyka M, Batra A, Moggi F, Walter M (Hrsg)  
Suchtmedizin, Elsevier, 2. Auflage 2025, S. 141-167.
  
198. **Myers JAC, Stafford T, Koychev I, Perneczky R, Bandmann O, Vaci N**  
Loneliness, social isolation, and effects on cognitive decline in patients with dementia: A retrospective cohort study using natural language processing.  
Alzheimers Dement (Amst). 2025 Jul 28;17(3):e70149. doi: 10.1002/dad2.70149.  
eCollection 2025 Jul-Sep. PMID: 40726520. IF 4.9
  
199. **Nadesalingam N, Kyrou A, Chapellier V, Maderthaner L, von Känel S, Wüthrich F, Nuoffer MG, Lefebvre S, Pavlidou A, Wobrock T, Gaebel W, Cordes J, Langguth B, Falkai P, Schneider-Axmann T, Strube W, Hasan A, Walther S**  
Testing a Motor Score Based on PANSS Ratings: A Proxy for Comprehensive Motor Assessment.  
Schizophr Bull. 2025 Jul 7;51(4):1162-1172. doi: 10.1093/schbul/sbae153.  
PMID: 39222718. IF 5.7

200. **Nemali A, Bernal J, Yakupov R, Singh D, Dyrba M, Incesoy EI, Mukherjee S, Peters O, Ersözlü E, Hellmann-Regen J, Preis L, Priller J, Spruth E, Altenstein S, Lohse A, Schneider A, Fliessbach K, Kimmich O, Wiltfang J, Hansen N, Schott B, Rostamzadeh A, Glanz W, Butryn M, Buerger K, Janowitz D, Ewers M, Perneczky R, Rauchmann B, Teipel S, Kilimann I, Goerss D, Laske C, Sodenkamp S, Spottke A, Coenjaerts M, Brosseron F, Lüsebrink F, Dechent P, Scheffler K, Hetzer S, Kleineidam L, Stark M, Jessen F, Duzel E, Ziegler G**  
SMAS: Structural MRI-based AD Score using Bayesian supervised VAE.  
Comput Biol Med. 2025 Sep;196(Pt C):110829. doi: 10.1016/j.combiomed.2025.110829. PMID: 40818206. IF (2024) 6.3
201. **Nierychlewski K, Paal M, Meinzer S, Musil R, Schwarz M**  
Optimizing therapeutic drug monitoring of mirtazapine - applying therapeutic reference range, concentration-dose ratio/dose-related concentration, and metabolic ratio in a naturalistic setting.  
Eur J Clin Pharmacol. 2025 Nov;81(11):1677-1687.  
doi: 10.1007/s00228-025-03907-6. PMID: 40830610. IF 3.5
202. **Nöhles VB, BERPpohl F, Schoofs N, Bathe-Peters R, Hilpert N, Dafsari FS, Reif-Leonhard C, Reif A, Schillo S, Arshad RS, Getty P, Falkai P, Schüle C, Wang E, Adli M, Papenfuß R, Meyer-Lindenberg A, Fritze S, Otte C, Piber D, Graumann L, Weyn-Banningh S, Bauer M, Lewitzka U, Spreer M, Clemens J, Rubarth K, Correll CU**  
Clinical and Treatment Characteristics of 3795 Adults Consecutively Hospitalized for Major Depressive Disorder in the OASIS-D Study.  
Depress Anxiety. 2025 Nov 26;2025:4470169. doi: 10.1155/da/4470169.  
eCollection 2025. PMID: 41347111. IF 2.7
203. **O'Connell KS, Koromina M, van der Veen T, Boltz T, David FS, Yang JMK, Lin KH, Wang X, Coleman JRI, Mitchell BL, McGrouther CC, Rangan AV, Lind PA, Koch E, Harder A, Parker N, Bendl J, Adorjan K, Agerbo E, Albani D, Alemany S, Alliey-Rodriguez N, Als TD, Andlauer TFM, Antoniou A, Ask H, Bass N, Bauer M, Beins EC, Bigdeli TB, Pedersen CB, Boks MP, Børte S, Bosch R, Brum M, Brumpton BM, Brunkhorst-Kanaan N, Budde M, Bybjerg-Grauholm J, Byerley W, Cabana-Domínguez J, Cairns MJ, Carpiello B, Casas M, Cervantes P, Chatzinakos C, Chen HC, Clarence T, Clarke TK, Claus I, Coombes B, Corfield EC, Cruceanu C, Cuellar-Barboza A, Czerski PM, Dafnas K, Dale AM, Dalkner N, Degenhardt F, DePaulo JR, Djurovic S, Drange OK, Escott-Price V, Fanous AH, Fellendorf FT, Ferrier IN, Forty L, Frank J, Frei O, Freimer NB, Fullard JF, Garnham J, Gizer IR, Gordon SD, Gordon-Smith K, Greenwood TA, Grove J, Guzman-Parra J, Ha TH, Hahn T, Haraldsson M, Hautzinger M, Havdahl A, Heilbronner U, Hellgren D, Herms S, Hickie IB, Hoffmann P, Holmans PA, Huang MC, Ikeda M, Jamain S, Johnson JS, Jonsson L, Kalman JL, Kamatani Y, Kennedy JL, Kim E, Kim J, Kittel-Schneider S, Knowles JA, Kogevinas M, Kranz TM, K...**  
See abstract for full author list →  
Genomics yields biological and phenotypic insights into bipolar disorder.  
Nature. 2025 Mar;639(8056):968-975. doi: 10.1038/s41586-024-08468-9.  
PMID: 39843750. IF 56.1

204. **Özlü S, Dyrba M, Grazia A, Brosseon F, Buerger K, Dechent P, Düzel E, Ewers M, Fliessbach K, Glanz W, Hansen N, Hellmann-Regen J, Hetzer S, Janowitz D, Kilimann I, Kronmüller M, Laske C, Lüsebrink F, Mengel D, Perneczky R, Peters O, Priller J, Ramirez A, Rauchmann BS, Rostamzadeh A, Schneider A, Sodenkamp S, Spottke A, Spruth EJ, Synofzik M, Wiltfang J, Heneka MT, Jessen F, Teipel S**  
CSF biomarkers of neuroinflammation are associated with regional atrophy.  
J Neurol. 2025 Dec 24;273(1):46. doi: 10.1007/s00415-025-13564-5.  
PMID: 41442069. IF 5.4
205. **Olderbak S, Hollweck R, Krowartz EM, Möckl J, Hoch E**  
Psychoactive Substance Use in Germany: Findings From the Epidemiological Survey of Substance Abuse (ESA) in 2024.  
Dtsch Arztebl Int. 2025 Nov 14;122(23):625-631. doi: 10.3238/arztebl.m2025.0157.  
PMID: 40956679. IF 8.7
206. **Olderbak S, Möckl J, Bergmann H, Krowartz EM, Preuss UW, Hoch E**  
Estimates of driving under the influence of cannabis in Germany in 2021 before the partial legalization.  
Sucht 2025; 71(1): 31-38. IF 0.8
207. **Olderbak S, Möckl J, Rauschert C, Schäfer E, Helmer S, Seitz NN, Hoch E**  
Predictors of changes in marijuana consumption in Germany during the covid-19 pandemic.  
Eur Arch Psychiatry Clin Neurosci. 2025 Mar;275(2):389-396.  
doi: 10.1007/s00406-024-01861-5. PMID: 38969751. IF 3.9
208. **Oliver D, Shin JI, Fusar-Poli P**  
Population-level prevention of severe mental disorders.  
Neurosci Biobehav Rev. 2025 Nov;178:106378. doi: 10.1016/j.neubiorev.2025.106378. PMID: 40976454. IF 8.5
209. **Oraki Kohshour M, Adorjan K, Budde M, Heilbronner M, Kalman JL, Navarro-Flores A, Reich-Erkelenz D, Schulte EC, Senner F, Vogl T, Anghelescu IG, Arolt V, Baune BT, Dannlowski U, Dietrich DE, Fallgatter AJ, Figge C, Lang FU, Juckel G, Konrad C, Reimer J, Reininghaus EZ, Schmauß M, Schmitt A, Spitzer C, Wiltfang J, Zimmermann J, Falkai P, Heilbronner U, Papiol S, Schulze TG**  
How variants in inflammatory mediator genes influence symptom severity of psychiatric disorders: Findings from the PsyCourse study.  
Psychiatry Res. 2025 Jun;348:116492. doi: 10.1016/j.psychres.2025.116492.  
PMID: 40239607. IF 5.1
210. **Oraki Kohshour M, Barth TK, Huber C, Klingl A, Grünert J, Heilbronner U, Budde M, Rübekeil M, Eberharter A, Müller T, Rossner MJ, Schmitt A, Falkai P, Raabe FJ, Papiol S, Imhof A, Schulze TG**  
Comparing the proteome profiling of plasma-derived extracellular vesicles in individuals with schizophrenia and healthy controls: a pilot study.  
Schizophr Res. 2025 Sep 12;285:87-94. doi: 10.1016/j.schres.2025.09.008.  
PMID: 40945317. IF 3.7
211. **Oraki Kohshour M, Heilbronner U, Mueller T, Rossner M, Papiol S, Schulze TG**  
The microRNA profile of brain-derived extracellular vesicles: A promising step forward in developing pharmacodynamic biomarkers for psychiatric disorders.  
Eur Neuropsychopharmacol. 2025 Jan;90:62-68. doi: 10.1016/j.euroneuro.2024.10.002. PMID: 39509833. IF 8.1

212. **Oraki Kohshour M, Papiol S, Tkachev A, Stekolshchikova E, Adorjan K, Budde M, Heilbronner U, Heilbronner M, Kalman JL, Reich-Erkelenz D, K Schaupp S, Senner F, Vogl T, Wiltfang J, Reininghaus EZ, Juckel G, Dannlowski U, Fallgatter AJ, Spitzer C, Schmauß M, von Hagen M, Falkai P, Khaitovich P, Schulze TG, Schulte EC**  
Investigating the association of the plasma lipidomic profile with cognitive performance and genetic risk in the PsyCourse study.  
Transl Psychiatry. 2025 Mar 28;15(1):105. doi: 10.1038/s41398-025-03323-5. PMID: 40155381. IF 7.5
  
213. **Palm U**  
[Nitrous oxide]. Between therapeutic application and abuse.  
Nervenarzt. 2025 Nov;96(6):595-596. doi: 10.1007/s00115-025-01811-z. PMID: 39945798. IF 1.1
  
214. **Palm U, Menke A, Brem A-K, Padberg F, Vogelmann U**  
Transcranial direct current stimulation for treatment of depression during inpatient psychotherapy: results from a psychosomatic hospital.  
International Neuropsychiatric Disease Journal 2025; 22(3): 82-92. IF -
  
215. **Palm U, Mesaric S, Eppele M, Backmund M**  
[Lethal nitrous oxide].  
Nervenarzt. 2025 Nov;96(6):590-592. doi: 10.1007/s00115-024-01780-9. PMID: 39550751. IF 1.1
  
216. **Pauwels P, Haack B, Toto S, Seifert J, Grohmann R, Heinze M, Zolk O, Proskynitopoulos PJ, Schneider M, Greiner T**  
Pharmacotherapy of psychiatric inpatients with mental and behavioral disorders caused by sedatives or hypnotics (F13): Results from an observational pharmacovigilance program between 2000 and 2017.  
Addict Sci Clin Pract. 2025 Jun 20;20(1):51. doi: 10.1186/s13722-025-00579-6. PMID: 40537875. IF 2.6
  
217. **Penzel N, Polosecki P, Addington J, Arango C, Asgari-Targhi A, Billah T, Bouix S, Calkins ME, Campbell DE, Cannon TD, Castro E, Cho KIK, Coleman MJ, Corcoran CM, Dwyer D, Frangou S, Fusar-Poli P, Glynn RJ, Haidar A, Harms MP, Jacobs GR, Kambeitz J, Kapur T, Kelly SM, Koutsouleris N, Abhinandan KR, Kucukemiroglu S, Kwon JS, Lewandowski KE, Li QS, Mantua V, Mathalon DH, Mittal VA, Nicholas S, Pandina GJ, Perkins DO, Potter A, Reichenberg A, Reinen J, Sand MS, Seitz-Holland J, Shah JL, Srinivasan V, Srivastava A, Stone WS, Torous J, Vangel MG, Wang J, Wolff P, Yao B, Anticevic A, Wolf DH, Zhu H, Bearden CE, McGorry PD, Nelson B, Kane JM, Woods SW, Kahn RS, Shenton ME; Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ); Cecchi G, Pasternak O**  
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.  
Schizophrenia (Heidelb). 2025 Apr 3;11(1):53. doi: 10.1038/s41537-025-00561-w. PMID: 40180950. IF 4.5
  
218. **Peralta V, Sánchez-Torres AM, Gil-Berrozpe G, de Jalón EG, Moreno-Izco L, Peralta D, Janda L, Cuesta MJ; SEGPEPs group**  
Neurocognitive and social cognitive correlates of social exclusion in psychotic disorders: a 20-year follow-up cohort study.  
Soc Psychiatry Psychiatr Epidemiol. 2025 Feb;60(2):413-426. doi: 10.1007/s00127-024-02742-x. PMID: 39090439. IF 3.5

219. **Perneckzy R, Darby D, Frisoni GB, Hyde R, Iwatsubo T, Mummery CJ, Park KH, van Beek J, van der Flier WM, Jessen F**  
Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus.  
J Prev Alzheimers Dis. 2025 Apr;12(4):100096. doi: 10.1016/j.tjpad.2025.100096. PMID: 39971671. IF 6.7
220. **Perneckzy R, Froelich L**  
Clinically meaningful benefit and real-world evidence in Alzheimer's disease research and care.  
Alzheimers Dement (N Y). 2025 Apr 24;11(2):e70. IF 12.8
221. **Perneckzy R, Quevenco FC, Hendrix J, Epelbaum S, Teunissen C, van der Flier WM, Suárez-Calvet M, Shi J, Mielke MM, Iwatsubo T, Palmqvist S, Hansson O**  
How can Alzheimer's disease blood-based biomarkers reach clinical practice?  
Alzheimers Dement (Amst). 2025 Nov 2;17(4):e70207. doi: 10.1002/dad2.70207. eCollection 2025 Oct-Dec. PMID: 41189609 090. doi: 10.1002/trc2.70090. eCollection 2025 Apr-Jun. PMID: 40291121. IF 4.9
222. **Peschka L, Schobel S, Arend C, Hajak G, Carbon CC, Schiltz K, Bergner-Köther R**  
The Relationship Between Offense-Supportive Cognitions and Childhood Trauma in Offending and Non-Offending Men with (Exclusive) Pede-, Hebe-, and Teleiophilia Who Seek Voluntary Treatment.  
Deviant Behavior, 2025: 1–20. <https://doi.org/10.1080/01639625.2025.2477254>. IF 1.7
223. **Plank SI, Nowak J, Pior A, Falter-Wagner CM**  
Comparison of face attention bias in adults with ASD, ADHD or comorbid ADHD+ASD.  
Soc Cogn Affect Neurosci. 2025 Jan 18;20(1):nsaf112. doi: 10.1093/scan/nsaf112. PMID: 41143567. IF 3.6
224. **Plank IS, Tepest R, Vogeley K, Falter-Wagner CM**  
The influence of interpersonal synchrony and autism on impressions of dyadic interactions: a preregistered study.  
Mol Autism. 2025 Jun 12;16(1):34. doi: 10.1186/s13229-025-00668-y. PMID: 40506740. IF 5.7
225. **Plank IS, Yurova A, Pior A, Nowak J, Bierlich AM, Papazov B, Shi Z, Falter-Wagner CM**  
Are prediction error modifications domain specific in autism but domain general in ADHD?  
Imaging Neurosci (Camb). 2025 Oct 17;3:IMAG.a.942. doi: 10.1162/IMAG.a.942. eCollection 2025. PMID: 41113941. IF 3.0
226. **Plewnia C, Brendel B, Schwippel T, Becker-Sadzio J, Hajiyevev I, Pross B, Strube W, Hasan A, Campana M, Padberg F, Mayer P, Kujovic M, Lorenz S, Schönfeldt-Lecuona C, Otte ML, Wolf RC, Höppner-Buchmann J, Serna-Higueta LM, Martus P, Fallgatter AJ**  
Theta burst stimulation of temporo-parietal cortex regions for the treatment of persistent auditory hallucinations: a multicentre, randomised, sham-controlled, triple-blind phase 3 trial in Germany.  
Lancet Psychiatry. 2025 Sep;12(9):638-649. doi: 10.1016/S2215-0366(25)00202-0. PMID: 40774272. IF 21.1

227. **Pogarell O, Koller G, Kramer J**  
[Opioid substitution therapy for opioid use disorder and legal framework in Germany].  
Fortschr Neurol Psychiatr 2025; 93: 530-544. IF 0.5
228. **Pogarell O, Kramer J, Koller G**  
[Involuntary hospitalisation according to german mental health laws - how to proceed in general practice?].  
MMW Fortschr Med. 2025 Apr;167(7):48-51. doi: 10.1007/s15006-025-4809-7. PMID: 40238005. IF -
229. **Pottier C, Küçükali F, Baker M, Batzler A, Jenkins GD, van Blitterswijk M, Vicente CT, De Coster W, Wynants S, Van de Walle P, Ross OA, Murray ME, Faura J, Haggarty SJ, van Rooij JG, Mol MO, Hsiung GR, Graff C, Öijersted L, Neumann M, Asmann Y, McDonnell SK, Baheti S, Josephs KA, Whitwell JL, Bieniek KF, Forsberg L, Heuer H, Lago AL, Geier EG, Yokoyama JS, Oddi AP, Flanagan M, Mao Q, Hodges JR, Kwok JB, Domoto-Reilly K, Synofzik M, Wilke C, Onyike C, Dickerson BC, Evers BM, Dugger BN, Munoz DG, Keith J, Zinman L, Rogaeva E, Suh E, Gefen T, Geula C, Weintraub S, Diehl-Schmid J, Farlow MR, Edbauer D, Woodruff BK, Caselli RJ, Donker Kaat LL, Huey ED, Reiman EM, Mead S, King A, Roeber S, Nana AL, Ertekin-Taner N, Knopman DS, Petersen RC, Petrucelli L, Uitti RJ, Wszolek ZK, Ramos EM, Grinberg LT, Tempini MLG, Rosen HJ, Spina S, Piguet O, Grossman M, Trojanowski JQ, Keene CD, Jin LW, Prudlo J, Geschwind DH, Rissman RA, Cruchaga C, Ghetti B, Halliday GM, Beach TG, Serrano GE, Arzberger T, Herms J, Boxer AL, Honig LS, Vonsattel JP, Lopez OL, Kofler J, White CL 3rd, Gearing M, Glass J, Rohrer JD, Irwin DJ, Lee EB, Van Deerlin V, Castellani R, Mesulam MM, Tartaglia MC, Finger EC, Tr...**  
**See abstract for full author list →**  
Deciphering distinct genetic risk factors for FTLT-TDP pathological subtypes via whole-genome sequencing.  
Nat Commun. 2025 Apr 25;16(1):3914. doi: 10.1038/s41467-025-59216-0. PMID: 40280976. IF 18.1
230. **Preuss UW, Hoch E**  
Synthetic cannabinoids: a narrative review.  
Suchttherapie 2025; 26(2): 85-94. IF 0.2
231. **Quattrone A, Franzmeier N, Huppertz HJ, Seneca N, Petzold GC, Spottke A, Levin J, Prudlo J, Düzel E; PASSPORT Study Group, the AL-108-231 Investigators, the Arise Investigators, the Tauros MRI Investigators, the DESCRIBE-PSP group; Höglinger GU**  
Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy.  
Mov Disord. 2025 Nov;40(11):2517-2530. doi: 10.1002/mds.70026. PMID: 40884249. IF 7.7
232. **Qela B, Damiani S, De Santis S, Groppi F, Pichiecchio A, Asteggiano C, Brondino N, Monteleone AM, Grassi L; MNESYS - Mood and Psychosis Sub-Project (Spoke 5); Politi P, Fusar-Poli P, Fusar-Poli L**  
Predictive coding in neuropsychiatric disorders: A systematic transdiagnostic review.  
Neurosci Biobehav Rev. 2025 Feb;169:106020. doi: 10.1016/j.neubiorev.2025.106020. PMID: 39828236. IF 8.5

233. **Radua J, Savage HS, Vilajosana E, Jamieson A, Abler B, Åhs F, Beckers T, Cardoner N, Cisler JM, Diniz JB, Bach DR, Elsenbruch S, Greening SG, Holt DJ, Kaczurkin AN, Keil A, Kindt M, Koch K, LaBar KS, Lam CL, Larson CL, Lonsdorf TB, Merz CJ, McLaughlin KA, Neria Y, Pine DS, van Reekum CM, Shackman AJ, Soriano-Mas C, Spoormaker VI, Stout DM, Straube B, Straube T, Tuominen L, Visser RM, Ahumada L, Arolt V, Batistuzzo MC, Bazán PR, Biggs EE, Cano M, Chavarría-Elizondo P, Cooper SE, Dannlowski U, de la Peña-Arteaga V, DeCross SN, Domschke K, Ehlers MR, Graner JL, Hamm AO, Herrmann MJ, Huggins AA, Icenhour A, Juaneda-Seguí A, Junghoefer M, Kircher T, Koelkebeck K, Kuhn M, Labrenz F, Lissek SM, Lotze M, Lueken U, Margraf J, Martínez-Zalacain I, Moeck R, Morriss J, Ortuño M, Pittig A, Porta-Casteras D, Richter J, Ridderbusch IC, Rief W, Roesmann K, Rosén J, Rußmann AN, Sjouwerman R, Spohrs J, Ströhle A, Suarez-Jimenez B, Ulrich M, Wittchen HU, Zhu X, Waller L, Walter H, Thompson PM, Bas-Hoogendam JM, Groenewold NA, J Stein D, Van der Wee NJ, Dunsmoor JE, Marquand AF, J Harrison B, Fullana MA**  
Neural correlates of human fear conditioning and sources of variability in 2199 individuals.  
Nat Commun. 2025 Aug 23;16(1):7869. doi: 10.1038/s41467-025-63078-x. PMID: 40849409. IF 18.1
234. **Ramos MRF, Goerigk S, Aparecida da Silva V, Cavendish BA, Pinto BS, Papa CHG, Resende JV, Klein I, Carneiro AM, de Sousa JP, Vidal KSM, Valiengo LDCL, Razza LB, Aparício LM, Martins L, Borrione L, Batista M, Moran NK, Dos Santos LA, Benatti R, Pelosof R, Padberg F, Brunoni AR**  
Accelerated Theta-Burst Stimulation for Treatment-Resistant Depression: A Randomized Clinical Trial.  
JAMA Psychiatry. 2025 May 1;82(5):442-450. doi: 10.1001/jamapsychiatry.2025.0013. PMID: 40042840. IF 18.0
235. **Rauchmann BS, Ersözlü E, Luedecke D, Franzmeier N, Perneczky R**  
Multimodal and longitudinal characterization of distinct tau and atrophy clusters in Alzheimer's disease spectrum.  
Sci Rep. 2025 May 25;15(1):18142. doi: 10.1038/s41598-025-98338-9. PMID: 40415101. IF 4.9
236. **Rausch J, Fangmeier T, Falter-Wagner CM, Ackermann H, Espelöer J, Hölzel LP, Riedel A, Ritvo A, Vogeley K, van Elst LT**  
A novel screening instrument for the assessment of autism in German language: validation of the German version of the RAADS-R, the RADS-R.  
Eur Arch Psychiatry Clin Neurosci. 2025 Dec;275(8):2449-2460. doi: 10.1007/s00406-024-01894-w. PMID: 39465450. IF 3.9
237. **Refisch A, Papiol S, Schumann A, Malchow B, Bär KJ**  
Polygenic risk for psychotic disorders in relation to cardiac autonomic dysfunction in unmedicated patients with schizophrenia.  
Eur Arch Psychiatry Clin Neurosci. 2025 Apr;275(3):863-871. doi: 10.1007/s00406-024-01933-6. PMID: 39503783. IF 3.9

238. **Reinhard MA**  
Aggression and Loneliness.  
In: Nelson, T.: The Handbook of Loneliness. Springer, 2025, p. 303-315.
239. **Reinhard MA**  
["But I have symptoms!" What to do when patients feel they are not being taken seriously].  
MMW Fortschr Med. 2025 Dec;167(21-22):50-53.  
doi: 10.1007/s15006-025-5437-y. PMID: 41361635. IF -
240. **Reinhard MA, Bertsch, K**  
Persönlichkeitsstörungen.  
In: Batra A, Wesselmann U, Philipsen A  
Verhaltenstherapie. Das Lehrbuch für Medizin und Psychologie. Kohlhammer, Stuttgart, 2025.
241. **Reinhard MA, Padberg F**  
Developing loneliness interventions for people with personality disorders: A call to action.  
Ann N Y Acad Sci. 2025 Jun;1548(1):56-65. doi: 10.1111/nyas.15367.  
PMID: 40369707. IF 4.5
242. **Rek S, Reinhard MA, Freeman D, Falkai P, Padberg F**  
A psychometric evaluation of the German Revised-Green et al. Paranoid Thoughts Scale (R-GPTS) in clinical and non-clinical groups.  
BMC Psychiatry. 2025 Nov 18;25(1):1095. doi: 10.1186/s12888-025-07538-0.  
PMID: 41254569. IF 4.6
243. **Reutimann S, Steiner J, Hübscher N, Voderholzer U, Meule A, Augsburg M**  
Evaluating the Construct Validity and Sensitivity to Change of the Klenico Depression Domain in Psychotherapeutic Inpatient Care: Instrument Validation Study.  
JMIR Form Res. 2025 Jul 24;9:e50504. doi: 10.2196/50504. PMID: 40706024.  
IF 2.4
244. **Rezaei A, Kocsis-Jutka V, Gunes ZI, Zeng Q, Kislinger G, Bauernschmitt F, Isilgan HB, Parisi LR, Kaya T, Franzenburg S, Koppenbrink J, Knogler J, Arzberger T, Farny D, Nuscher B, Katona E, Dhingra A, Yang C, Gouna G, LaClair KD, Janjic A, Enard W, Zhou Q, Hagan N, Ofengeim D, Beltrán E, Gokce O, Simons M, Liebscher S, Edbauer D**  
Correction of dysregulated lipid metabolism normalizes gene expression in oligodendrocytes and prolongs lifespan in female poly-GA C9orf72 mice.  
Nat Commun. 2025 Apr 11;16(1):3442. doi: 10.1038/s41467-025-58634-4.  
PMID: 40216746. IF 18.1
245. **Richter D, Breilmann J, Becker T, Allgöwer A, Kilian R, Hasan A, Falkai P, Ajayi K, Halms T, Brieger P, Frasch K, Heres S, Jäger M, Kuthmann A, Putzhammer A, Riedel-Heller SG, Schneeweiß B, Schwarz M, Kösters M, Gühne U**  
[Self-help offers for people with severe mental illness: who uses which format?].  
Nervenarzt. 2025 Jan;96(1):57-65. doi: 10.1007/s00115-024-01749-8.  
PMID: 39438290. IF 1.1

246. **Richter M, Emden D, Leenings R, Winter NR, Mikolajczyk R, Massag J, Zwiky E, Borgers T, Redlich R, Koutsouleris N, Falguera R, Edwin Thanarajah S, Padberg F, Reinhard MA, Back MD, Morina N, Buhlmann U, Kircher T, Dannlowski U; MBB consortium; FOR2107 consortium; PRONIA consortium; Hahn T, Opel N**  
Generalizability of clinical prediction models in mental health.  
Mol Psychiatry. 2025 Aug;30(8):3632-3639. doi: 10.1038/s41380-025-02950-0.  
PMID: 40108256. IF 10.4
  
247. **Rieder T, Robjant K, Chibashimba A, Schmitt S, Goerigk S, Elbert T, Koebach A, Jobst A**  
The impact of childhood maltreatment on treatment outcomes for posttraumatic stress symptoms and aggression in male former combatants using narrative exposure therapy [NET] - results from a RCT in Eastern democratic Republic of Congo.  
Confl Health. 2025 Oct 4;19(1):67. doi: 10.1186/s13031-025-00710-z.  
PMID: 41046251. IF 6.4
  
248. **Rieder B, Stoll Y, Falarowski C, Gertzen M, Kise G, Koller G, Koch S, Laux P, Luch A, Rahofer A, Rüther T, Mallock-Ohnesorg N, Nowak D, Schulz T, Zaslon ME, Turcios A, Rabenstein A, Pieper E**  
Smoking Topography, Nicotine Kinetics, and Subjective Smoking Experience of Mentholated and Non-Mentholated Heated Tobacco Products in Occasional Smokers.  
Toxics. 2025 Sep 6;13(9):757. doi: 10.3390/toxics13090757.  
PMID: 41012378. IF 4.9
  
249. **Riemerschmid C, Hoch E, Wittekind CE; Advisory Board of the German Addiction Care Statistical Service; Schwarzkopf L**  
Cocaine Use Disorder in German outpatient addiction care - A trend analysis.  
J Subst Use Addict Treat. 2025 Nov;178:209769. doi: 10.1016/j.josat.2025.209769.  
PMID: 40744436. IF 2.8
  
250. **Roell L, Lindner C, Maurus I, Keeser D, Malchow B, Schmitt A, Falkai P**  
Neural and somatic mechanisms driving clinical improvements in post-acute schizophrenia spectrum disorders.  
Eur Psychiatry. 2025 Oct 27;68(1):e162. doi: 10.1192/j.eurpsy.2025.10129.  
PMID: 41140039. IF 7.9
  
251. **Roell L, Wunderlich S, Roell D, Raabe F, Wagner E, Shi Z, Schmitt A, Falkai P, Stoecklein S, Keeser D**  
How to measure functional connectivity using resting-state fMRI? A comprehensive empirical exploration of different connectivity metrics.  
Neuroimage. 2025 May 15;312:121195. doi: 10.1016/j.neuroimage.2025.121195.  
PMID: 40216213. IF 5.3
  
252. **Roemer-Cassiano SN, Wagner F, Evangelista L, Rauchmann BS, Dehsarvi A, Steward A, Dewenter A, Biel D, Zhu Z, Pescoller J, Gross M, Perneczky R, Malpetti M, Ewers M, Schöll M, Dichgans M, Höglinger GU, Brendel M, Jäkel S, Franzmeier N**  
Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease.  
Sci Transl Med. 2025 Jan 22;17(782):eadp2564.  
doi: 10.1126/scitranslmed.adp2564. PMID: 39841807. IF 15.6

253. **Rösner S, Soyka M**  
Pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit. Etablierte Wirkstoffe und neue Ansätze.  
Neurologie & Psychiatrie 2025;3: 6-8. IF -
254. **Rojnic Kuzman M, Nordentoft M, Raballo A, Mohr P, Fiorillo A, Dom G, Mihajlovic G, Jendricko T, Chumakov E, Barjaktarov S, Carpinello B, Patarák M, Martin L, Dudek D, Samochowiec J, Taube M, Courtet P, Babic D, Racetovic G, Catthoor K, Arango C, Maruta N, Basar K, Vahip S, Szekeres G, Lien L, Popova A, Zhelev R, Jääskeläinen E, Delic M, Chkonia E, Chichai J, Telles-Correia D, Cosman DCM, Beezhold J, Falkai P**  
Schizophrenia treatment preferences of psychiatrists versus guidelines: A European perspective.  
Eur Psychiatry. 2025 Aug 1;68(1):e107. doi: 10.1192/j.eurpsy.2025.10072. PMID: 40745910. IF 7.9
255. **Rüther T, Gertzen M**  
Psychiatrische, neurologische und internistische Folgeschäden.  
In: Soyka M, Batra A, Moggi F, Walter M (Hrsg)  
Suchtmedizin, Elsevier, 2. Auflage 2025, S. 281-283.
256. **Salazar de Pablo G, Aymerich C, Chart-Pascual JP, Solmi M, Torres-Cortes J, Abdelhafez N, Catalan A, Corbeil O, Adamo N, Shaw P, Fusar-Poli P, Cortese S**  
Occurrence of Psychosis and Bipolar Disorder in Individuals With Attention-Deficit/Hyperactivity Disorder Treated With Stimulants: A Systematic Review and Meta-Analysis.  
JAMA Psychiatry. 2025 Nov 1;82(11):1103-1112. doi: 10.1001/jamapsychiatry.2025.2311. PMID: 40900605. IF 18.0
257. **Salokangas RKR, Wenzel J, From T, Ilonen T, Armio RL, Laurikainen H, Tuominen L, Walta M, Ruef A, Bonivento C, Dwyer D, Brambilla P, Wood S, Upthegrove R, Borgwardt S, Meisenzahl E, Rosen M, Lichtenstein T, Ruhrmann S, Pantelis C, Lencer R, Bertolino A, Schultze-Lutter F, Riecher A, Kambeitz J, Kambeitz-Ilankovic L, Koutsouleris N, Hietala J; PRONIA consortium**  
Active treatment of affective disturbances may improve functional outcomes in patients in the early state of psychosis: Results of the PRONIA study.  
Eur Psychiatry. 2025 Oct 1;68(1):e151. doi: 10.1192/j.eurpsy.2025.10113. PMID: 41030061. IF 7.9
258. **Sarisik E, Popovic D, Keeser D, Khuntia A, Schiltz K, Falkai P, Pogarell O, Koutsouleris N**  
EEG-based Signatures of Schizophrenia, Depression, and Aberrant Aging: A Supervised Machine Learning Investigation.  
Schizophr Bull. 2025 May 8;51(3):804-817. doi: 10.1093/schbul/sbae150. PMID: 39248267. IF 5.7
259. **Saur S, Weisel KK, Lang C, Fuhrmann LM, Meurer N, Reichl D, Zink M, Heepe P, Hillemacher T, Braunwarth WD, Falkai P, Koller G, Kiderman Y, Kraus T, Kornhuber J, Spitzer P, Bönsch D, Stemmler M, Hildebrand A, Steins-Loeber S, Berking M**  
Evaluation of a Smartphone App Intervention with Telephone Guidance as Transitional Support from Inpatient Treatment to Continuing Care for Individuals with Alcohol Use Disorder: Results from a Randomized Controlled Trial.  
Psychother Psychosom. 2025;94(5):311-323. doi: 10.1159/000545817. PMID: 40414214. IF 9.0

260. **Scharfenberg D, Kalbe E, Balzer-Geldsetzer M, Berg D, Hilker-Roggendorf R, Kassubek J, Liepelt-Scarfone I, Mollenhauer B, Reetz K, Riedel O, Roeske S, Schulz JB, Storch A, Trenkwalder C, Witt K, Wittchen HU, Dodel R, Ophey A**  
A network perspective on cognition in individuals with Parkinson's disease.  
*Alzheimers Dement (Amst)*. 2025 Feb 24;17(1):e70091. doi: 10.1002/dad2.70091.  
eCollection 2025 Jan-Mar. PMID: 39996032. IF 4.9
  
261. **Scheithauer S, Hoffmann J, Lang C, Fenz D, Berens MM, Köster AM, Panchyrz I, Harst L, Adorjan K, Apfelbacher C, Ciesek S, Denking CM, Drosten C, Geraedts M, Hecker R, Hoffmann W, Karch A, Koch T, Krefting D, Lieb K, Meerpohl JJ, Rehfuess EA, Skoetz N, Sopka S, von Lengerke T, Wiegand H, Schmitt J**  
Pandemic Preparedness - A Proposal for a Research Infrastructure and its Functionalities for a Resilient Health Research System.  
*Gesundheitswesen*. 2025 Dec;87(S 03):S334-S343. doi: 10.1055/a-2365-9179.  
PMID: 39009032. IF 1.1
  
262. **Schiemainski PLA, Kunz JI, Nagl S, Wolf J, Goerigk S, Jobst A, Padberg F, Reinhard MA**  
Interpersonal Problems and the Alternative Model of Personality Disorders: An Investigation Using the Interpersonal Circumplex.  
*Personal Ment Health*. 2025 Nov;19(4):e70045. doi: 10.1002/pmh.70045.  
PMID: 41261013. IF 2.8
  
263. **Schillok H, Gensichen J, Panagioti M, Gunn J, Junker L, Lukaschek K, Jung-Sievers C, Sterner P, Kaupe L, Dreischulte T, Ali MK, Aragonès E, Bekelman DB, Herbeck Belnap B, Carney RM, Chwastiak LA, Coventry PA, Davidson KW, Ekstrand ML, Flehr A, Fletcher S, Hölzel LP, Huijbregts K, Mohan V, Patel V, Richards DA, Rollman BL, Salisbury C, Simon GE, Srinivasan K, Unützer J, van der Feltz-Cornelis CM, Wells KB, Zimmermann T, Bühner M; POKAL Group**  
Effective Components of Collaborative Care for Depression in Primary Care: An Individual Participant Data Meta-Analysis.  
*JAMA Psychiatry*. 2025 Sep 1;82(9):868-876. doi: 10.1001/jamapsychiatry.2025.0183. PMID: 40136273. IF 18.0
  
264. **Schiltz K, Fischer K**  
Sucht und Forensische Psychiatrie.  
In: Soyka M, Batra A, Moggi F, Walter M (Hrsg)  
*Suchtmedizin*, Elsevier, 2. Auflage 2025, S. 487-498.
  
265. **Schirge PM, Perneczky R, Taoka T, Ruiz-Rizzo AL, Ersoezlue E, Forbrig R, Guersel S, Kurz C, Brendel M, Hellmann-Regen J, Priller J, Schneider A, Jessen F, Düzel E, Buerger K, Teipel S, Laske C, Peters O, Spruth E, Fliessbach K, Rostamzadeh A, Glanz W, Janowitz D, Kilimann I, Sodenkamp S, Ewers M, Rauchmann BS**  
Perivascular space and white matter hyperintensities in Alzheimer's disease: associations with disease progression and cognitive function.  
*Alzheimers Res Ther*. 2025 Mar 18;17(1):62. doi: 10.1186/s13195-025-01707-9.  
PMID: 40098158. IF 8.9

266. **Schlegl S, Hirler F, Gerich A, Højlund M, Stice E, Wade T, Wilfley D, Downs J, Voderholzer U, Perry J, Haas V, Solmi M, Correll C**  
Comparative efficacy and acceptability of interventions for universal, selective and indicated prevention of eating disorders: study protocol for a systematic review and network meta-analysis.  
J Eat Disord. 2025 Apr 25;13(1):72. doi: 10.1186/s40337-025-01244-8.  
PMID: 40281541. IF 5.7
267. **Schmitt A, Roell L, Maurus I, Falkai P**  
Aerobic exercise therapy in severe mental disorders: from methods to underlying mechanisms.  
Eur Arch Psychiatry Clin Neurosci. 2025 Apr;275(3):591-593.  
doi: 10.1007/s00406-025-01991-4. PMID: 40085249. IF 3.9
268. **Schneider F, Arolt V, Bauer M, Domschke K, Philipsen A, Voderholzer U**  
[Starting shot for the "new" Der Nervenarzt: interdisciplinary psychiatry].  
Nervenarzt. 2025 Jan;96(1):1-2. doi: 10.1007/s00115-024-01794-3.  
PMID: 39869177. IF 1.1
269. **Schneider LS, Freiesleben SD, van Breukelen G, Wang X, Brosseon F, Heneka MT, Teipel S, Kleineidam L, Stark M, Roy-Kluth N, Wagner M, Spottke A, Schmid M, Roeske S, Laske C, Munk MH, Perneczky R, Rauchmann BS, Buerger K, Janowitz D, Düzel E, Glanz W, Jessen F, Rostamzadeh A, Wiltfang J, Bartels C, Kilimann I, Schneider A, Fließbach K, Priller J, Spruth EJ, Hellmann-Regen J, Peters O**  
Linking higher amyloid beta 1-38 (A $\beta$ (1-38)) levels to reduced Alzheimer's disease progression risk.  
Alzheimers Dement. 2025 Feb;21(2):e14545. doi: 10.1002/alz.14545.  
PMID: 39868793. IF 12.8
270. **Schöllner NS, Glos A, Möckl J, Krowartz EM, Hoch E, Olderbak S**  
Age-period-cohort analysis of past 12-month cannabis use in Germany (1995-2021).  
Addiction. 2025 Sep;120(9):1759-1769. doi: 10.1111/add.70087.  
PMID: 40537976. IF 5.9
271. **Schoenweger P, Eder J, Pfeiffer L, Falkai P, Kirschneck M, Simon MS, Ditzen-Janotta C, Brunoni AR, Coenen M, Dong MS, Gensichen J, Glocker C, Koutsouleris N, Musil R, Schmitt A, Jung-Sievers C**  
Measuring social environment factors of inpatients and outpatients with depression in Germany: a cross-sectional study.  
BMJ Ment Health. 2025 Apr 3;28(1):e301359. doi: 10.1136/bmjment-2024-301359.  
PMID: 40185492. IF 6.6
272. **Schottdorf J, Musil R**  
Behandlung von chronischem Rückenschmerz mit expositionsgestützter Trauma-Akupunkturtherapie (EX.TRACT).  
Deutsche Zeitschrift für Akupunktur 2025; 68(3): 144-148. IF -
273. **Schwarz J, Gertzen M, Rabenstein A, Straßburger M, Horstmann A, Pogarell O, Rütger T, Karch S**  
What Chemsex does to the brain - neural correlates (ERP) regarding decision making, impulsivity and hypersexuality.  
Eur Arch Psychiatry Clin Neurosci. 2025 Feb;275(1):227-240.  
doi: 10.1007/s00406-024-01856-2. PMID: 38969754. IF 3.9

274. **Schüle C**  
[Acute suicidal tendencies - what can the GP do?].  
MMW Fortschr Med. 2025 Apr;167(7):40-47. doi: 10.1007/s15006-025-4839-1.  
PMID: 40238004. IF -
275. **Seidenbecher S, Kaufmann J, Schöne M, Dobrowolny H, Schiltz K, Frodl T, Steiner J, Bogerts B, Nickl-Jockschat T**  
Association between white matter microstructural changes and aggressiveness. A case-control diffusion tensor imaging study.  
Neuroimage Clin. 2025;45:103712. doi: 10.1016/j.nicl.2024.103712.  
PMID: 39603043. IF 4.2
276. **Semler E, Herpich F, Zellner L, Zwick S, Zwanzger P, Brunnauer A**  
The impact of aerobic endurance training on cognitive performance in schizophrenic inpatients in a clinical routine setting.  
Eur Arch Psychiatry Clin Neurosci. 2025 Apr;275(3):641-651.  
doi: 10.1007/s00406-024-01773-4. PMID: 38502204. IF 3.9
277. **Senyüz B, Vonderlin R, Claus C, Mahalingam S, Koch S, Voderholzer U, Teismann T, Kleindienst N, Böhnke JR, Lis S, Boritz T, McMain S, Bohus M**  
The Borderline Symptom List-Interview: development and psychometric evaluation of an observer-based instrument for assessing symptom severity in borderline personality disorder.  
Borderline Personal Disord Emot Dysregul. 2025 Aug 28;12(1):33.  
doi: 10.1186/s40479-025-00310-6. PMID: 40877981. IF 3.2
278. **Serra-Navarro M, Heilbronner M, Solé B, Borràs R, Martinez-Arán A, Adorjan K, Navarro-Flores A, Oraki Kohshour M, Reich-Erkelenz D, Schulte EC, Senner F, Anghelescu IG, Arolt V, Baune BT, Dannlowski U, Dietrich DE, Fallgatter AJ, Figge C, Jäger M, Juckel G, Konrad C, Reimer J, Reininghaus EZ, Schmauß M, Schmitt A, Spitzer C, Wiltfang J, Zimmermann J, Papiol S, Heilbronner U, Falkai P, Schulze TG, Vieta E, Torrent C, Budde M, Amoretti S**  
Influence of Sex and Diagnosis on Clinical Variables and Neurocognitive Performance in Severe Mental Illness. Results From the PsyCourse Study.  
Acta Psychiatr Scand. 2025 Sep 3. doi: 10.1111/acps.70026.  
PMID: 40899437. IF 4.7
279. **Shanta O, Klein M, Sacks M, MacDonald JR, Maihofer A, Ahangari M, Engchuan W, Thiruvahindrapuram B, Guevara J, Hong O, Huguet G, Sønderby I, Kalyuzhny M, Adams MJ, Adolfsson R, Agartz I, Aiello AE, Alda M, Allardyce J, Amstadter AB, Andlauer TFM, Andreassen OA, Artigas MS, Austin SB, Ayub M, Baker DG, Bass N, Baune BT, Bayas M, Berger K, Biernacka JM, Bigdeli T, Bisson JI, Blackwood D, Boks M, Braff D, Bramon E, Breen G, Brueckl T, Bryant RA, Bulik CM, Buxbaum J, Cairns MJ, Caldas-de-Almeida JM, Campbell M, Champion D, Carr VJ, Castela E, Chaumette B, Cichon S, Cohen D, Corvin A, Craddock N, Crosbie J, Czamara D, Dannlowski U, Degenhardt F, Delahanty DL, Dempfle A, Desachy G, Di Florio A, Dickerson FB, Djurovic S, Domschke K, Douglas L, Drange OK, Duncan LE, Edenberg HJ, Esko T, Faraone S, Feeny NC, Forstner AJ, Franke B, Frye M, Fu DJ, Fullerton JM, Gareeva A, Garvert L, Gatt JM, Gejman P, Geschwind DH, Giegling I, Glatt SJ, Glessner J, Goes FS, Gordon-Smith K, Grabe H, Green MJ, Green MF, Greenwood T, Grigoriu-Serbanescu M, Gur RE, Gur RC, Guzman-Parra J, Haavik J, Hahn T, Hakonarson H, Hallmayer J, Hamshire ML, Hartmann AM, Hassan A, Hayward C, Hebebrand J, Hemmings SMJ, Herms...See abstract for full author list →**

A cross-disorder analysis of CNVs finds novel loci and dose-dependent relationships of genes to psychiatric traits.  
medRxiv [Preprint]. 2025 Jul 16;2025.07.11.25331310.  
doi: 10.1101/2025.07.11.25331310. PMID: 40791719

280. **Sharew NT, Clark SR, Papiol S, Heilbronner U, Degenhardt F, Fullerton JM, Hou L, Shekhtman T, Adli M, Akula N, Akiyama K, Ardu R, Arias B, Hasler R, Richard-Lepouriel H, Perroud N, Backlund L, Bhattacharjee AK, Bellivier F, Benabarre A, Bengesser S, Biernacka JM, Birner A, Marie-Claire C, Cervantes P, Chen HC, Chillotti C, Cichon S, Cruceanu C, Czerski PM, Dalkner N, Del Zompo M, DePaulo JR, Étain B, Jamain S, Falkai P, Forstner AJ, Frisen L, Frye MA, Gard S, Garnham JS, Goes FS, Grigoriu-Serbanescu M, Fallgatter AJ, Stegmaier S, Ethofer T, Biere S, Petrova K, Schuster C, Adorjan K, Budde M, Heilbronner M, Kalman JL, Kohshour MO, Reich-erkelenz D, Schaupp SK, Schulte EC, Senner F, Vogl T, Anghelescu IG, Arolt V, Dannlowski U, Dietrich DE, Figge C, Jäger M, Lang FU, Juckel G, Konrad C, Reimer J, Schmauß M, Schmitt A, Spitzer C, von Hagen M, Wiltfang J, Zimmermann J, Andlauer TFM, Fischer A, Bermpohl F, Ritter P, Matura S, Gryaznova A, Falkenberg I, Yildiz C, Kircher T, Schmidt J, Koch M, Gade K, Trost S, Haussleiter IS, Lambert M, Rohenkohl AC, Kraft V, Grof P, Hashimoto R, Hauser J, Herms S, Hoffmann P, Jiménez E, Kahn JP, Kassem L, Kuo PH, Kato T, Kelsoe J, Kittel-Schnei...**

**See abstract for full author list →**

Pathway-Specific Polygenic Scores for Predicting Clinical Lithium Treatment Response in Patients With Bipolar Disorder.

Biol Psychiatry Glob Open Sci. 2025 Jun 25;5(5):100558.

doi: 10.1016/j.bpsgos.2025.100558. PMID: 40821394. IF 4.0

281. **Shi Z, Allenmark F, Theisinger LA, Pistorius RL, Glasauer S, Müller HJ, Falter-Wagner CM**  
Predictive Processing in Autism Spectrum Disorder: The Atypical Iterative Prior Updating Account.  
Biol Psychiatry Glob Open Sci. 2025 Feb 17;5(3):100468. doi: 10.1016/j.bpsgos.2025.100468. eCollection 2025 May. PMID: 40231304. IF 4.0
282. **Sigrist C, Bechdorf A, Bertsch K, Bullenkamp R, Busse M, Darrelmann UG, Dempfle A, Driessen M, Frodl T, Kersting JM, Kesik J, Matzke B, Neukel C, Niessen E, Nückel S, Oertel V, Padberg F, Philipsen A, Pink D, Reif A, Reinhard M, Steuwe C, Wolkenstein L, Herpertz SC, Consortium TM**  
A mechanism-based group psychotherapy approach to aggressive behavior (MAAP) in borderline personality disorder: a multicenter randomized controlled clinical trial.  
Trials. 2025 Aug 2;26(1):265. doi: 10.1186/s13063-025-08985-6. PMID: 40753432. IF 2.1
283. **Singh D, Brima Y, Levin F, Becker M, Hiller B, Hermann A, Villar-Munoz I, Beichert L, Bernhardt A, Buerger K, Butryn M, Dechent P, Düzel E, Ewers M, Fliessbach K, Freiesleben SD, Glanz W, Hetzer S, Janowitz D, Görß D, Kilimann I, Kimmich O, Laske C, Levin J, Lohse A, Luesebrink F, Munk M, Perneczky R, Peters O, Preis L, Priller J, Prudlo J, Prychynenko D, Rauchmann BS, Rostamzadeh A, Roy-Kluth N, Scheffler K, Schneider A, Droste Zu Senden L, Schott BH, Spottke A, Synofzik M, Wiltfang J, Jessen F, Weber MA, Teipel SJ, Dyrba M**  
An unsupervised XAI framework for dementia detection with context enrichment.  
Sci Rep. 2025 Nov 12;15(1):39554. doi: 10.1038/s41598-025-26227-2. PMID: 41224940. IF 4.9

284. **Singh D, Grazia A, Reiz A, Hermann A, Altenstein S, Beichert L, Bernhardt A, Buerger K, Butryn M, Dechent P, Duzel E, Ewers M, Fliessbach K, Freiesleben SD, Glanz W, Hetzer S, Janowitz D, Kilimann I, Kimmich O, Laske C, Levin J, Lohse A, Luesebrink F, Munk M, Perneczky R, Peters O, Preis L, Priller J, Prudlo J, Rauchmann BS, Rostamzadeh A, Roy-Kluth N, Scheffler K, Schneider A, Schneider LS, Schott BH, Spottke A, Spruth EJ, Synofzik M, Wiltfang J, Jessen F, Teipel SJ, Dyrba M; ADNI; AIBL; FTLDNI; study groups**  
A computational ontology framework for the synthesis of multi-level pathology reports from brain MRI scans.  
J Alzheimers Dis. 2025 Nov;108(1\_suppl):S258-S273. doi: 10.1177/13872877251331222. PMID: 4025503. IF 3.4
285. **Smith A, Hachen S, Weinberg A, Falkai P, Guttormsen S, Liebreiz M**  
The weight of office? A scoping review of mental health issues and risk factors in elected politicians across democratic societies.  
Int J Soc Psychiatry. 2025 Mar;71(2):223-238. doi: 10.1177/00207640241291523 . PMID: 39535138. IF 2.7
286. **Soldini A, Vogelmann U, Aust S, Goerigk S, Plewnia C, Fallgatter A, Normann C, Frase L, Zwanzger P, Kammer T, Schönfeldt-Lecuona C, Vural G, Bajbouj M, Padberg F, Burkhardt G**  
Neurocognitive function as outcome and predictor for prefrontal transcranial direct current stimulation in major depressive disorder: an analysis from the DepressionDC trial.  
Eur Arch Psychiatry Clin Neurosci. 2025 Sep;275(6):1715-1724. doi: 10.1007/s00406-024-01759-2. PMID: 38407625. IF 3.9
287. **Solé B, Montejo L, Budde M, Valentí M, Borràs R, Martín-Parra S, Ruiz A, Martínez-Aran A, Adorjan K, Heilbronner M, Navarro-Flores A, Oraki Kohshour M, Reich-Erkelenz D, Schulte EC, Senner F, Anghelescu IG, Arolt V, Baune BT, Dannlowski U, Dietrich DE, Fallgatter AJ, Figge C, Juckel G, Konrad C, Reimer J, Reininghaus EZ, Schmauß M, Spitzer C, Wiltfang J, Zimmermann J, Falkai P, Vieta E, Schulze TG, Torrent C, Heilbronner U, Papiol S**  
Unravelling the Link Between Body Mass Index and Cognitive Performance in Individuals With Bipolar Disorder and Exploration of PRS Moderation Effect: Findings From the PsyCourse Study.  
Acta Psychiatr Scand. 2025 Dec;152(6):451-461. doi: 10.1111/acps.70028. PMID: 40887816. IF 4.7
288. **Solmi M, Thompson T, Cortese S, Estradé A, Agorastos A, Radua J, Dragioti E, Vancampfort D, Thygesen LC, Aschauer H, Schlögelhofer M, Aschauer E, Schneeberger AA, Huber CG, Hasler G, Conus P, Do Cuénod KQ, von Känel R, Arrondo G, Fusar-Poli P, Gorwood P, Llorca PM, Krebs MO, Scanferla E, Kishimoto T, Rabbani G, Skonieczna-Żydecka K, Brambilla P, Favaro A, Takamiya A, Zocante L, Colizzi M, Bourgin J, Kamiński K, Moghadasin M, Seedat S, Matthews E, Wells J, Vassilopoulou E, Gadelha A, Su KP, Kwon JS, Kim M, Lee TY, Papsuev O, Manková D, Boscutti A, Gerunda C, Saccon D, Righi E, Monaco F, Croatto G, Cereda G, Demurtas J, Brondino N, Veronese N, Enrico P, Politi P, Ciappolino V, Pfennig A, Bechdolf A, Meyer-Lindenberg A, Kahl KG, Domschke K, Bauer M, Koutsouleris N, Winter S, Borgwardt S, Bitter I, Balazs J, Czobor P, Unoka Z, Mavridis D, Tsamakakis K, Bozikas VP, Tunvirachaisakul C, Maes M, Rungnirundorn T, Supasitthumrong T, Haque A, Brunoni AR, Costardi CG, Schuch FB, Polanczyk G, Luiz JM, Fonseca L, Aparicio LV, Valvassori SS, Nordentoft M, Vendsborg P, Hoffmann SH, Sehli J,**

**Sartorius N, Heuss S, Guinart D, Hamilton J, Kane J, Rubio J, Sand M, Koyanagi A, Solanes A, Andreu-B...** See abstract for full author list →  
 Collaborative Outcomes Study on Health and Functioning During Infection Times (COH-FIT): Global and Risk-Group Stratified Course of Well-Being and Mental Health During the COVID-19 Pandemic in Adolescents.  
*J Am Acad Child Adolesc Psychiatry.* 2025 Apr;64(4):499-519.  
 doi: 10.1016/j.jaac.2024.07.932. PMID: 39581373. IF 9.6

289. **Solmi M, Thompson T, Cortese S, Estradé A, Agorastos A, Radua J, Dragioti E, Vancampfort D, Thygesen LC, Aschauer H, Schlögelhofer M, Aschauer E, Schneeberger A, Huber CG, Hasler G, Conus P, Cuénod KQD, von Känel R, Arrondo G, Fusar-Poli P, Gorwood P, Llorca PM, Krebs MO, Scanferla E, Kishimoto T, Rabbani G, Skonieczna-Żydecka K, Brambilla P, Favaro A, Takamiya A, Zocante L, Colizzi M, Bourgin J, Kamiński K, Moghadasin M, Seedat S, Matthews E, Wells J, Vassilopoulou E, Gadelha A, Su KP, Kwon JS, Kim M, Lee TY, Papsuev O, Manková D, Boscutti A, Gerunda C, Saccon D, Righi E, Monaco F, Croatto G, Cereda G, Demurtas J, Brondino N, Veronese N, Enrico P, Politi P, Ciappolino V, Pfennig A, Bechdolf A, Meyer-Lindenberg A, Kahl KG, Domschke K, Bauer M, Koutsouleris N, Winter S, Borgwardt S, Bitter I, Balazs J, Czobor P, Unoka Z, Mavridis D, Tsamakias K, Bozikas VP, Tunvirachaisakul C, Maes M, Rungnirundorn T, Supasitthumrong T, Haque A, Brunoni AR, Costardi CG, Schuch FB, Polanczyk G, Luiz JM, Fonseca L, Aparicio LV, Valvassori SS, Nordentoft M, Vendsborg P, Hoffmann SH, Sehli J, Sartorius N, Heuss S, Guinart D, Hamilton J, Kane J, Rubio J, Sand M, Koyanagi A, Solanes A, Andreu-Bern...**  
 See abstract for full author list →  
 Collaborative outcomes study on health and functioning during infection times (COH-FIT): Insights on modifiable and non-modifiable risk and protective factors for wellbeing and mental health during the COVID-19 pandemic from multivariable and network analyses.  
*Eur Neuropsychopharmacol.* 2025 Jan;90:1-15.  
 doi: 10.1016/j.euroneuro.2024.07.010. PMID: 39341043. IF 8.1
290. **Solomon P, Budde M, Kohshour MO, Adorjan K, Heilbronner M, Navarro-Flores A, Papiol S, Reich-Erkelenz D, Schulte EC, Senner F, Vogl T, Kaurani L, Krüger DM, Sananbenesi F, Pena T, Burkhardt S, Schütz AL, Anghelescu IG, Arolt V, Baune BT, Dannlowski U, Dietrich DE, Fallgatter AJ, Figge C, Juckel G, Konrad C, Lang FU, Reimer J, Reininghaus EZ, Schmauß M, Spitzer C, Wiltfang J, Zimmermann J, Fischer A, Falkai P, Schulze TG, Heilbronner U, Poschmann J**  
 Disease severity across psychiatric disorders is linked to pro-inflammatory cytokines.  
*Brain Behav Immun.* 2025 Jun 10;129:359-372. doi: 10.1016/j.bbi.2025.06.004. PMID: 40505822. IF 7.5
291. **Solomon P, Kaurani L, Budde M, Guiné JB, Krüger DM, Riquin K, Pena T, Burkhardt S, Fourgeux C, Adorjan K, Heilbronner M, Kalman JL, Kohshour MO, Papiol S, Reich-Erkelenz D, Schaupp SK, Schulte EC, Senner F, Vogl T, Anghelescu IG, Arolt V, Baune BT, Dannlowski U, Dietrich DE, Fallgatter AJ, Figge C, Juckel G, Konrad C, Reimer J, Reininghaus EZ, Schmauß M, Spitzer C, Wiltfang J, Zimmermann J, Schütz AL, Sananbenesi F, Sauvaget A, Falkai P, Schulze TG, Fischer A, Heilbronner U, Poschmann J**  
 Integrative analysis of miRNA expression profiles reveals distinct and common molecular mechanisms underlying broad diagnostic groups of severe mental disorders.  
*Mol Psychiatry.* 2025 Sep;30(9):4364-4383. doi: 10.1038/s41380-025-03018-9. PMID: 40263528. IF 10.4

- 292. Soyka M**  
Approved medications for opioid use disorder : current update.  
Expert Opin Pharmacother. 2025 Jun;26(9):1055-1069.  
doi: 10.1080/14656566.2025.2507124. PMID: 40370106. IF 3.4
- 293. Soyka M**  
Diagnostische Kriterien für Suchterkrankungen.  
In: Soyka M, Batra A, Moggi F, Walter M (Hrsg)  
Suchtmedizin, Elsevier, 2. Auflage 2025, S. 3-13.
- 294. Soyka M**  
Notfallsituationen.  
In: Soyka M, Batra A, Moggi F, Walter M (Hrsg)  
Suchtmedizin, Elsevier, 2. Auflage 2025, S. 389-403.
- 295. Soyka M**  
[Therapy of substance use disorders in correctional settings].  
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.  
2025 Dec;68(12):1380-1387. doi: 10.1007/s00103-025-04149-8.  
PMID: 41152621. IF 1.6
- 296. Soyka M, Batra A**  
Abhängigkeit von Schlaf- und Beruhigungsmitteln (ICD-10 F13.2).  
In: Voderholzer U (Hrsg). Therapie psychischer Erkrankungen.  
State of the Art 2026. Elsevier, Urban & Fischer, 2025, 21. Auflage, S. 80-91.
- 297. Soyka M, Batra A, Moggi F, Walter M (Hrsg)**  
Suchtmedizin, Elsevier, 2. Auflage 2025
- 298. Soyka M, Rösner S**  
Modern pharmacotherapy guidance for treating alcohol use disorders.  
Expert Opin Pharmacother. 2025 Feb;26(2):147-156.  
doi: 10.1080/14656566.2024.2445734. PMID: 39702947. IF 3.4
- 299. Soyka M, Schmidt P, Wittchen H-U, Bühringer G**  
Retention rates in opioid maintenance treatment with methadone and  
buprenorphine – results from a 6-year observational study.  
Heroin Addict Relat Clin Probl 2025; 27:9.  
<https://doi.org/10.62401/2531-4122-2025-9>. IF 0.6
- 300. Springer N, Echtler L, Volkmann P, Hühne-Landgraf A, Hochenbleicher J, Hoch E, Koller G, Landgraf D**  
DAILY - A personalized circadian *Zeitgeber* therapy as an adjunctive treatment for  
alcohol use disorder patients: results of a pilot trial.  
Front Psychiatry. 2025 Feb 7;16:1477895. doi: 10.3389/fpsyt.2025.1477895.  
eCollection PMID: 39990170. IF 3.8
- 301. Sprüngli-Toffel E, Studerus E, Curtis L, Conchon C, Alameda L, Bailey B, Caron C, Haase C, Gros J, Herbrecht E, Huber CG, Riecher-Rössler A, Conus P, Solida A, Armando M, Kapsaridi A, Ducommun MM, Klauser P, Plessen KJ, Urben S, Edan A, Nanzer N, Navarro AL, Schneider M, Genoud D, Michel C, Kindler J, Kaess M, Oliver D, Fusar-Poli P, Borgwardt S, Andreou C**  
Individualized pretest risk estimates to guide treatment decisions in patients with  
clinical high risk for psychotic disorders.  
Span J Psychiatry Ment Health. 2025 Apr-Jun;18(2):133-140.  
doi: 10.1016/j.sjpmh.2024.09.001. PMID: 39303874. IF 2.6

302. **Stahl K, Papiol S, Budde M, Heilbronner M, Oraki Kohshour M, Falkai P, Schulze TG, Heilbronner U, Bickeböller H**  
Aggregating SNPs Improves Filtering for False Positive Associations Post-Imputation.  
G3 (Bethesda). 2025 May 8;15(5):jkaf043. doi: 10.1093/g3journal/jkaf043. PMID: 40053832. IF 2.4
  
303. **Stampf A, Schwarzkopf L, Batalla A, Feingold D, Fischer B, Hoch E; Advisory Board of the German Addiction Care Statistical Service**  
Cannabis-related treatment demand at the eve of German cannabis legalization - a 20-years trend analysis.  
Eur Arch Psychiatry Clin Neurosci. 2025 Mar;275(2):365-378. doi: 10.1007/s00406-024-01832-w. PMID: 38951248. IF 3.9
  
304. **Stefanelli R, Estradé A, Azis M, Stefana A, Bonoldi I, Damiani S, De Micheli A, Floris V, Provenzani U, Ballan L, Jauhar S, Vitoratou S, Stahl D, Solmi M, Correll CU, Pfennig A, Young AH, Fusar-Poli P**  
The semi-structured interview for bipolar at-risk states (SIBARS): psychometric properties and validation.  
J Affect Disord. 2025 Oct 15;387:119529. doi: 10.1016/j.jad.2025.119529. PMID: 40441640. IF 5.7
  
305. **Stefanelli R, Orlandi M, Bouter DC, Fusar-Poli P, Tonna M, Borgatti R, Mensi MM**  
IQ and socio-occupational functioning in relation to obsessive-compulsive symptoms severity in a clinical sample of adolescents.  
Sci Rep. 2025 Apr 23;15(1):14021. doi: 10.1038/s41598-025-98475-1. PMID: 40269005. IF 4.9
  
306. **Stoffers-Winterling JM, Wiegand HF, Broll J, Schäfer SK, Adorjan K, Tüscher O, Lieb K**  
[The COVID-19 pandemic in Germany: mental health trajectories, resilient and vulnerable groups].  
Nervenarzt. 2025 May;96(3):266-271. doi: 10.1007/s00115-025-01824-8. PMID: 40180657. IF 1.1
  
307. **Streit F, Awasthi S, Hall AS, Braun A, Niarchou M, Marouli E, Babajide O, Frank J, Zillich L, Callies CM, Avetyan D, Zillich E, Naamanka J, Gonzalez J, Harder A, Lu Y, Aherrahrou Z, Ahmad ZU, Ask H, Batzler A, Benros ME, Brand-de Wilde OM, Brunak S, Bruun MT, Christoffersen LA, Colodro-Conde L, Coombes BJ, Corfield EC, Dahmen N, Didriksen M, Dinh KM, Djurovic S, Dowsett J, Drange OK, Dukal H, Edelmann S, Erikstrup C, Espinola MK, Fassbinder E, Faucon A, de Sá DSF, Foo JC, Gilles M, Gutiérrez-Zotes A, Hansen TF, Haraldsson M, Harper RP, Havdahl A, Heilbronner U, Herms S, Hjalgrim H, Hübel C, Jacob GA, Aagaard B, Jorgensen A, Jungkunz M, Kleindienst N, Knoblich N, Koglin S, Kraft J, Krebs K, Lee CW, Lin Y, Lis S, Lisoway A, Malogiannis IA, Martinsen A, Maslahati T, Merz K, Meyer-Lindenberg A, Mikkelsen S, Mikkelsen C, Mobascher A, Muntané G, Oddsson A, Ostrowski SR, Palviainen T, Pedersen OB, Pedersen G, Quinn L, Reinhard MA, Ruths FA, Schott BH, Schredl M, Schwarz E, Schwarze CE, Schwinn M, Send T, Sigurdsson E, Simon-Keller K, Skuladottir AT, Soler J, Sonley A, Sørensen E, Stefansson H, Straub P, Suvisaari J, Tesli M, Træholt J, Ullum H, Völker MP, Walters GB, Wang R, Witt ...**  
**See abstract for full author list →**  
Genome-wide association study of borderline personality disorder identifies 11 loci and highlights shared risk with mental and somatic disorders.  
medRxiv [Preprint]. 2025 Aug 12:2024.11.12.24316957.

doi: 10.1101/2024.11.12.24316957. PMID: 40832388

- 308. Streetz CM, Szejko N, Pisarenko A, Fremer C, Teske J, Brunnauer A, Müller-Vahl KR**  
Case Report: Effect of medicinal cannabis on fitness to drive in a patient with Tourette Syndrome and ADHD.  
Front Psychiatry. 2025 Aug 18;16:1595649. doi: 10.3389/fpsy.2025.1595649. eCollection 2025. PMID: 40901261. IF 3.8
- 309. Strom NI, Gerring ZF, Galimberti M, Yu D, Halvorsen MW, Abdellaoui A, Rodriguez-Fontenla C, Sealock JM, Bigdeli T, Coleman JR, Mahjani B, Thorp JG, Bey K, Burton CL, Luykx JJ, Zai G, Alemany S, Andre C, Askland KD, Bäckman J, Banaj N, Barlassina C, Nissen JB, Bienvenu OJ, Black D, Bloch MH, Børte S, Bosch R, Breen M, Brennan BP, Brentani H, Buxbaum JD, Bybjerg-Grauholm J, Byrne EM, Cabana-Dominguez J, Camarena B, Camarena A, Cappi C, Carracedo A, Casas M, Cavallini MC, Ciullo V, Cook EH, Crosby J, Cullen BA, De Schipper EJ, Delorme R, Djurovic S, Elias JA, Estivill X, Falkenstein MJ, Fundin BT, Garner L, Girona C, Goes FS, Grados MA, Grove J, Guo W, Haavik J, Hagen K, Harrington K, Havdahl A, Höffler KD, Hounie AG, Hucks D, Hultman C, Janecka M, Jenike E, Karlsson EK, Kelley K, Klawohn J, Krasnow JE, Krebs K, Lange C, Lanzagorta N, Levey D, Lindblad-Toh K, Macciardi F, Maher B, Mathes B, McArthur E, McGregor N, McLaughlin NC, Meier S, Miguel EC, Mulhern M, Nestadt PS, Nurmi EL, O'Connell KS, Osiecki L, Ousdal OT, Palviainen T, Pedersen NL, Piras F, Piras F, Potluri S, Rabionet R, Ramirez A, Rauch S, Reichenberg A, Riddle MA, Ripke S, Rosário MC, Sampaio AS, Schiele MA, Skogholt A...**  
**See abstract for full author list →**  
Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder.  
Nat Genet. 2025 Jun;57(6):1389-1401. doi: 10.1038/s41588-025-02189-z. PMID: 40360802. IF 25.5
- 310. Stüben N, Muscheidt R, Kiefer F, Soyka M**  
Web-based interventions for treatment-seeking individuals with hazardous alcohol consumption: analysis of clinical characteristics and motives for abstinence.  
Alcohol Alcohol. 2025 Mar 25;60(3):agaf015. doi: 10.1093/alcalc/agaf015. PMID: 40173316. IF 2.3
- 311. Sumiyoshi T, Campanella S, Giordano GM, Ishii R, Pogarell O**  
Understanding the Pathophysiology of Mental Diseases and Early Diagnosis Thanks to Electrophysiological Tools: Some Insights and Empirical Facts.  
Clin EEG Neurosci. 2025 Sep;56(5):410-418. doi: 10.1177/15500594241227485. PMID: 38238934. IF 2.1
- 312. Tang VM, Aaronson S, Abdelghani M, Baeken C, Barbour T, Brunoni AR, Bulteau S, Carpenter LL, Croarkin PE, Daskalakis ZJ, Fitzgerald PB, Kozel FA, Le Foll B, Mehta UM, Noda Y, Padberg F, Plewnia C, Su H, van Eijndhoven P, van Exel E, van Oostrom I, Vila-Rodriguez F, Voineskos D, Wilson S, Blumberger DM**  
Assessment and Management of Concurrent Substance Use in Patients Receiving Repetitive Transcranial Magnetic Stimulation for Depressive, Obsessive-Compulsive, Psychotic, and Trauma-Related Disorders: A Delphi Consensus Study and Guideline.  
Am J Psychiatry. 2025 May 1;182(5):438-451. doi: 10.1176/appi.ajp.20240403. PMID: 40103354. IF 15.9

313. **Thaon de Saint André S, Heinig I, Arolt V, Bartnick C, Dannlowski U, D  
eckert J, Domschke K, Fydrich T, Goerigk S, Hamm AO, Hollandt M, Hoyer J,  
Kircher T, Koelkebeck K, Lueken U, Margraf J, Neudeck P, Pauli P, Richter J,  
Rief W, Schneider S, Straube B, Ströhle A, Wittchen HU, Pittig A**  
Same same but different: Threat expectancy change and fear reduction as  
readouts of exposure rationales are only weakly associated and contribute  
differentially to treatment outcome in anxiety disorders.  
Behav Res Ther. 2025 Nov;194:104856. doi: 10.1016/j.brat.2025.104856.  
PMID: 41067133. IF 4.3
314. **Tognin S, Vieira S, Oliver D, Cullen AE, Kempton MJ, Fusar-Poli P, Mechelli A,  
Dazzan P, Merritt K, Maat A, de Haan L, Lawrie SM, van Amelsvoort T,  
Arango C, Nelson B, Galderisi S, Bressan R, Kwon JS, Mizrahi R;  
PSYSCAN Consortium; Kahn RS, McGuire P**  
PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the  
clinical high risk for psychosis sample.  
Schizophrenia (Heidelb). 2025 Apr 17;11(1):66. doi: 10.1038/s41537-025-00598-x.  
PMID: 40246889. IF 4.5
315. **Tritsch J, Völkel A, Hasan A, Padberg F, Strube W**  
Challenges in determining motor threshold for therapeutic repetitive transcranial  
magnetic stimulation: A paradigmatic case report of radiculopathy.  
Psychiatry Clin Neurosci. 2025 Dec;79(12):863-864.  
doi: 10.1111/pcn.13900. PMID: 41014220. IF 5.9
316. **Tuominen L, Armio RL, Hansen JY, Walta M, Koutsouleris N, Laurikainen H,  
Salokangas RKR, Misic B, Hietala J**  
Molecular, physiological and functional features underlying antipsychotic  
medication use related cortical thinning.  
Transl Psychiatry. 2025 Apr 6;15(1):129. doi: 10.1038/s41398-025-03336-0.  
PMID: 40189580. IF 7.5
317. **van der Veen T, Tesfaye M, Yang JMK, Boltz T, David FS, Crinion S,  
Koromina M, Andlauer TFM, Bigdeli TB, Coombes BJ, Greenwood TA,  
Panagiotaropoulou G, Parker N, Sung H, Bass N, Coleman JRI,  
Guzman-Parra J, Kalman JL, McGrouther CC, Mitchell BL, Rangan AV, Scott K,  
Shadrin A, Smith DJ, Vreeker A, Adorjan K, Albani D, Alemany S, Alliey-  
Rodriguez N, Antoniou A, Bauer M, Beins EC, Boks MP, Bosch R, Brumpton  
BM, Brunkhorst-Kanaan N, Budde M, Byerley W, Cabana-Domínguez J,  
Cairns MJ, Carpiello B, Casas M, Cervantes P, Chatzinakos C, Clarke TK,  
Claus I, Cruceanu C, Cuellar-Barboza A, Czerski PM, Dafnas K, Dale AM,  
Dalkner N, DePaulo JR, Degenhardt F, Djurovic S, Escott-Price V, Fanous AH,  
Fellendorf FT, Ferrier IN, Forty L, Frank J, Frei O, Freimer NB, Garnham J,  
Gizer IR, Gordon SD, Gordon-Smith K, Hahn T, Marian L, Harder A,  
Hautzinger M, Heilbronner U, Hellgren D, Herms S, Hickie IB, Hoffmann P,  
Holmans PA, Jamain S, Jonsson L, Kennedy JL, Kittel-Schneider S,  
Knowles JA, Koch E, Kogevinas M, Kranz TM, Kushner SA, Lavebratt C,  
Lawrence J, Leber M, Lind PA, Lucae S, Lundberg M, MacIntyre DJ, Maier W,  
Maihofer AX, Malaspina D, Manchia M, Maratou E, Martinsson L, McInnis MG,  
McKay JD, ...See abstract for full author list →**  
Immune, Developmental, and Synaptic Pathways Define Bipolar Disorder Clinical  
Heterogeneity.  
medRxiv [Preprint]. 2025 Jun 27:2025.06.23.25330155.  
doi: 10.1101/2025.06.23.25330155. PMID: 40666370

318. **van Deursen D, Mittendorfer-Rutz E, Taipale H, Pettersson E, McGuire P, Fusar-Poli P, Joyce DW, Albert N, Erlangsen A, Nordentoft M, Hjorthøj C, Cervenka S, Cullen AE**  
Prevalence and predictors of healthcare use for psychiatric disorders at 9 years after a first episode of psychosis: a Swedish national cohort study.  
BMJ Ment Health. 2025 Mar 26;28(1):e301248.  
doi: 10.1136/bmjment-2024-301248.PMID: 40139843. IF 6.6
319. **van Hattem T, Chang KY, Tik M, Taylor P, Björklund J, Bulubas L, Padberg F, Keeser D, Campana M**  
Contralateral prefrontal and network engagement during left DLPFC 10 Hz rTMS: an interleaved TMS-fMRI study in healthy adults.  
Neuroimage Clin. 2025 Aug 6;48:103862. doi: 10.1016/j.nicl.2025.103862.  
PMID: 40816029. IF 4.2
320. **Vetter CS, Bender A, Dwyer DB, Montembeault M, Ruef A, Chisholm K, Kambeitz-Ilankovic L, Antonucci LA, Ruhrmann S, Kambeitz J, Rosen M, Lichtenstein T, Riecher-Rössler A, Upthegrove R, Salokangas RKR, Hietala J, Pantelis C, Lencer R, Meisenzahl E, Wood SJ, Brambilla P, Borgwardt S, Falkai P, Bertolino A, Koutsouleris N; PRONIA Consortium**  
Exploring the predictive value of structural covariance networks for the diagnosis of schizophrenia.  
Front Psychiatry. 2025 Jun 9;16:1570797. doi: 10.3389/fpsyt.2025.1570797.  
eCollection 2025. PMID: 40551821. IF 3.8
321. **Vidal KS, Cavendish BA, Goerigk S, Pita Batista M, Oliveira Lima AR, Pinto BS, Neto Domingos AA, de Sousa JP, Pelosof R, Bertola L, Silva V, Suemoto CK, Razza LB, Bikson M, Piloni G, Charvet L, Silva PHR, Brunoni AR**  
Transcranial direct current stimulation plus cognitive training for cognitive symptoms in patients with post-acute sequelae of SARS-CoV-2 infection: A randomized, double-blind, sham-controlled trial.  
Brain Stimul. 2025 Aug 21;18(5):1608-1616. doi: 10.1016/j.brs.2025.08.018.  
PMID: 40848897. IF 9.7
322. **Voderholzer U, Hohagen F**  
Therapie psychischer Erkrankungen. State of the Art 2026.  
Elsevier/Urban & Fischer, 2025, 21. Auflage.
323. **Voderholzer U, Naab S, Cuntz U, Schlegl S**  
Anorexia nervosa-an update.  
Nervenarzt. 2025 May;96(3):220-229. doi: 10.1007/s00115-025-01819-5.  
PMID: 40261365. IF 1.1
324. **Vogelmann U, Stadler M, Soldini A, Chang KY, Chen M, Bulubas L, Dechantsreiter E, Plewnia C, Fallgatter A, Langguth B, Normann C, Frase L, Zwanzger P, Kammer T, Schönfeldt-Lecuona C, Kamp D, Bajbouj M, Hunold A, Schramm S, Priller J, Palm U, Charvet L, Keeser D, Burkhardt G, Padberg F**  
A comparative analysis of technical data: At-home vs. in-clinic application of transcranial direct current stimulation in depression.  
Brain Stimul. 2025 Jul-Aug;18(4):1097-1105. doi: 10.1016/j.brs.2025.05.103.  
PMID: 40374109. IF 9.7

325. **Volkmann P, Geiger AEI, Hühne-Landgraf A, Miljanovic N, Bly J, Engl T, Potschka H, Rossner MJ, Landgraf D**  
Integrity of the circadian clock determines regularity of high-frequency and diurnal LFP rhythms within and between brain areas.  
Mol Psychiatry. 2025 May;30(5):1859-1875. doi: 10.1038/s41380-024-02795-z. PMID: 39472662. IF 10.4
326. **von Trott J, Eberle C, Koutsouleris N**  
[Early detection of psychoses in primary care settings: Timely identification and targeted treatment for clinical high risk patients].  
MMW Fortschr Med. 2025 Apr;167(7):36-39. doi: 10.1007/s15006-025-4800-3. PMID: 40238003. IF -
327. **Wallman P, Estradé A, Azis M, Haining K, Liang X, Spencer TJ, Diederens K, Provenzani U, Uhlhaas PJ, Fusar-Poli P**  
The ENTER study (E-Detection Tool for Emerging Mental Disorders): general population recruitment and data integrity in online screening for psychosis risk.  
Front Psychiatry. 2025 Nov 18;16:1665854. doi: 10.3389/fpsy.2025.1665854. eCollection 2025. PMID: 41340857. IF 3.8
328. **Walter M, Soyka M**  
Opiode.  
In: Soyka M, Batra A, Moggi F, Walter M (Hrsg)  
Suchtmedizin, Elsevier, 2. Auflage 2025, S. 209-233.
329. **Wang E, Björklund J, Strasburger M, Schwarz J, Neumeier K, Rabenstein A, Koller G, Gertzen M, Rütger T**  
Komm kuscheln - Serumoxotizinkonzentration als potenzieller Biomarker bei Chemsex-Usern.  
Sucht 2025; 71(1): 39-46. IF 0.8
330. **Wang H, Chang TS, Dombroski BA, Cheng PL, Si YQ, Tucci A, Patil V, Valiente-Banuet L, Li C, Farrell K, Mclean C, Molina-Porcel L, Rajput A, De Deyn PP, Le Bastard N, Gearing M, Donker Kaat L, Van Swieten JC, Doppler E, Ghetti BF, Newell KL, Troakes C, de Yébenes JG, Rábano-Gutierrez A, Meller T, Oertel WH, Respondek G, Stamelou M, Arzberger T, Roeber S, Müller U, Hopfner F, Pastor P, Brice A, Durr A, Le Ber I, Beach TG, Serrano GE, Hazrati LN, Litvan I, Rademakers R, Ross OA, Galasko D, Boxer AL, Miller BL, Seeley WW, Van Deerlin VM, Lee EB, White CL 3rd, Morris HR, de Silva R, Crary JF, Goate AM, Friedman JS, Compta Y, Leung YY, Coppola G, Naj AC, Wang LS; PSP Genetics Study Group; Dalgard C, Dickson DW, Höglinger GU, Tzeng JY, Geschwind DH, Schellenberg GD, Lee WP**  
Copy Number Variation and Haplotype Analysis of 17q21.31 Reveals Increased Risk Associated with Progressive Supranuclear Palsy and Gene Expression Changes in Neuronal Cells.  
Mov Disord. 2025 May;40(5):950-961. doi: 10.1002/mds.30150. PMID: 40055946. IF 7.7
331. **Wei Y, Lorenz C, Siafis S, Schneider-Thoma J, Kim DD, Wu H, Nomura N, Dong S, Furukawa Y, Zhu Y, Bighelli I, Hansen WP, Vogelmann U, Strube W, Li C, Davis JM, Smith RC, Salanti G, Padberg F, Leucht S**  
Non-invasive brain stimulation augmentation therapy for treatment-resistant schizophrenia: a systematic review and network meta-analysis.  
EClinicalMedicine. 2025 Oct 22;89:103583. doi: 10.1016/j.eclinm.2025.103583. eCollection 2025 Nov. PMID: 41210378. IF 12.8

332. **Weilnhammer V, Rothkirch M, Yilmaz D, Fritsch M, Ptasczynski LE, Reichenbach K, Rödiger L, Corlett P, Sterzer P**  
N-methyl-d-aspartate receptor hypofunction causes recurrent and transient failures of perceptual inference.  
Brain. 2025 May 13;148(5):1531-1539. doi: 10.1093/brain/awaf011.  
PMID: 39821016. IF 12.6
333. **Weitz J, Hammerl T, Halms T, Rabenstein A, Rüther T, Hasan A**  
Procurement pathways of illegal substances in Germany: a systematic review with implications for prevention, harm reduction, and drug policy.  
Curr Addict Rep 2025; 12:60. IF 4.2
334. **Wertz M, Kaltenbach F, Kirchmann R, Brenzinger N, Schiltz K**  
Prävention und Intervention bei sexualisierter Gewalt gegen Kinder.  
Sexuologie 2025; 32(3/4): 137-153. IF -
335. **Werz J, Tuschen-Caffier B, Vorderholzer U**  
The Relationship Between Therapeutic Alliance, Early Symptom Change, and Outcome Among In-Patients With Anorexia Nervosa.  
Int J Eat Disord. 2025 Dec;58(12):2378-2391. doi: 10.1002/eat.24524.  
PMID: 40990205. IF 4.7
336. **Wiegand A, Friske M, Edelmann S, Bender A, Fischer L, Zill P, Koller G, Bakalkin G, Sommer WH, Hansson AC, Nieratschker V**  
Validation of *GDAP1* and *HECW2* as Epigenetic Markers of Alcohol Use Disorder in Blood and Brain.  
Int J Mol Sci. 2025 Nov 8;26(22):10840. doi: 10.3390/ijms262210840.  
PMID: 41303328. IF 5.6
337. **Wiegand HF, Adorjan K, Stoffers-Winterling J, Scheithauer S, Schmitt J, Tüscher O, Falkai P, Lieb K**  
[Mental health and mental healthcare as elements of pandemic and crisis preparedness].  
Nervenarzt. 2025 May;96(3):272-277. doi: 10.1007/s00115-025-01822-w.  
PMID: 40169414. IF 1.1
338. **Wiegand HF, Hölzel L, Tüscher O, Lieb K, Falkai P, Adorjan K**  
Mental health services in Germany - Structures, outcomes and future challenges.  
Int Rev Psychiatry. 2025 May-Jun;37(3-4):253-270.  
doi: 10.1080/09540261.2025.2479601. PMID: 40708412. IF 2.3
339. **Wölflle UC, Beck F, Werner N, Pitchika V, Heck K, Folwaczny M, Schwendicke F, Boudriot E, Greiner SK, Hasan A, Falkai P, Löhrs L, Bumm CV**  
Association of psychosis and oral health: case-control study.  
Clin Oral Investig. 2025 Aug 6;29(9):397. doi: 10.1007/s00784-025-06463-6.  
PMID: 40764865. IF 3.6
340. **Wölfling K, Eichenberg C, Lemenager T, Basenach L, Dreier M, Rüther T, Salbach H, Bischof A, Rumpf HJ**  
Guideline on the treatment of general internet use disorder.  
Sucht 2025; 71(2): 87-92. IF 0.8

341. **Wolf J, Goerigk S, Midderhoff F, Burkhardt G, Bühner M, Köhler S, Falkai P, Jobst A, Padberg F, Reinhard MA**  
Temporal interaction of suicidal ideations and behaviors with loneliness in persistent depressive disorder - a feasibility study using ecological momentary assessment.  
Eur Arch Psychiatry Clin Neurosci. 2025 Jun;275(4):1253-1259.  
doi: 10.1007/s00406-024-01931-8. PMID: 39488639. IF 3.9
342. **Wunderlich S, Keeser D, Spaeth J, Yilmaz D, Maurus I, Alici C, Schmitt A, Falkai P, Stoecklein S, Roell L**  
Reducing functional dysconnectivity in people with schizophrenia spectrum disorders.  
BJPsych Open. 2025 Nov 10;11(6):e271. doi: 10.1192/bjo.2025.10892.  
PMID: 41208396. IF 4.0
343. **Yakimov V, Jäger I, Roell L, Boudriot E, Meisinger V, Campana M, Krčmář L, Halstead S, Warren N, Siskind D, Maurus I, Hasan A, Falkai P, Schmitt A, dieffRaabe FJ, Keeser D; CDP-Working Group; Wagner E, Moussiopoulou J**  
Relationship between blood-cerebrospinal fluid barrier integrity, cardiometabolic, and inflammatory factors in schizophrenia-spectrum disorders.  
Brain Behav Immun Health. 2025 May 27;47:101024. doi: 10.1016/j.bbih.2025.101024. eCollection 2025 Aug. PMID: 40529789. IF 3.8
344. **Yilmaz D, Papiol S, Keeser D, Cole JH, Malchow B, Walter H, Meyer-Lindenberg A, Hirjak D, Hasan A, Schmitt A, Falkai P, Maurus I, Roell L**  
Brain age gap reduction following exercise mirrors clinical improvements in schizophrenia spectrum disorders.  
Neuroimage Clin. 2025;48:103881. doi: 10.1016/j.nicl.2025.103881.  
PMID: 41067091. IF 4.2
345. **Younesi P, Haas C, Dreischulte T, Schmitt A, Gensichen J, Lukaschek K; POKAL-Group**  
Brief interventions for suicidal ideation in primary care: a systematic review.  
BMC Prim Care. 2025 May 15;26(1):167. doi: 10.1186/s12875-025-02848-4.  
PMID: 40375159. IF 2.9
346. **Young AH, Llorca PM, Fagiolini A, Falkai P, Cardoner N, Nielsen RE, Blomqvist O, Godinov Y, Rive B, Diels J, Mulhern-Haughey S, Reif A**  
Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.  
Br J Psychiatry. 2025 Feb;226(2):72-78. doi: 10.1192/bjp.2024.124.  
PMID: 39618237. IF 8.5
347. **Young AH, Llorca PM, Fagiolini A, Falkai P, Cardoner N, Nielsen RE, Blomqvist O, Godinov Y, Rive B, Diels J, Mulhern-Haughey S, Reif A**  
Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial - ERRATUM.  
Br J Psychiatry. 2025 Sep;227(3):659-660. doi: 10.1192/bjp.2025.10308.  
PMID: 40488357. IF -

348. **Zhelyazkova A, Koletzko S, Adorjan K, Schrimf A, Völk S, Koletzko L, Fabry-Said A, Osterman A, Badell I, Eden M, Choukér A, Tuschen M, Koletzko B, Hao Y, Tu L, Török HP, Wichert SP, Le Thi TG; Members of RisCoin Study Group**  
Implementation and Adherence of a Custom Mobile Application for Anonymous Bidirectional Communication Among Nearly 4000 Participants: Insights from the Longitudinal RisCoin Study.  
Infect Dis Rep. 2025 Jul 24;17(4):88. doi: 10.3390/idr17040088.  
PMID: 40863250. IF 2.6
349. **Zöbl L, Frühauf A, Heimbeck A, Voderholzer U, Kopp M**  
Therapeutic climbing as an adjunctive treatment for psychiatric inpatients: A qualitative study.  
J Behav Ther Exp Psychiatry. 2025 Dec;89:102058.  
doi: 10.1016/j.jbtep.2025.102058. PMID: 40854625. IF 2.3